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bFGF   basic fibroblast growth factor 
BMP   bone morphogenetic protein 
BMPR  bone morphogenetic protein receptor 
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CDK   cycling-dependent kinase 
CDKN2A  cyclin-dependent kinase inhibitor 2A 
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CSC   cancer stem cells 
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ECM   extracellular matrix 
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EDB   extra-domain B 
EGF   epidermal growth factor 
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FSA   furin-specific activity 
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GDF   growth differentiation factor 
GIC   glioma-initiating cells 
Glut   glucose transporter 
GM-CSF  granulocyte-macrophage colony-stimulating factor 
GSK3B  glycogen synthase kinase-3β 
GTPase  guanosine triphosphate hydrolase  
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HCMEC  human cerebral microvascular endothelial cells 
HDAC   histone deacetylase 
HLA   human leukocyte antigen 
ICGC   International Cancer Genome Consortium 
IDH   isocitrate dehydrogenase 
IGF   insulin-like growth factor 
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IKK   inhibitor of kB kinase 
IL   interleukin 
iPS cells  induced pluripotent stem cells 
JNK   Jun amino-terminal kinase 
L1CAM  L1 cell adhesion molecule 
LAP   latency associated peptide 
LIF   leukemia inhibitory factor 
LLC   large latent complex 
LTBP   latent TGF-β binding protein 
MH   mad homology 
MAPK   mitogen-activated protein kinase 
MCH   melanin-concentrating hormone  
MDM   mouse double minute 
MEK mitogen-activated protein/extracellular signal-regulated kinase 
kinase 
MGMT  06-methylguanine-DNA methyltransferase 
MMP   matrix metalloprotease 
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MRI   magnetic resonance imaging 
mTOR  mammalian target of rapamycin 
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NF   neurofibromin 
NF-kB   nuclear factor-κB 
NGF   nerve growth factor 
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PCV   procarbazine, CCNU, vincristin 
PDGF   platelet-derived growth factor 
PDGFR  platelet-derived growth factor receptor 
PI3K   phosphatidylinositol 3-kinase 
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R-SMAD  receptor-regulated SMAD 
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TGFβR  transforming growth factor-β receptor 
TIMP   tissue inhibitor matrix metalloprotease 
TLR   toll-like receptor 
TMZ   temozolomide 
TNF   tumor necrosis factor 
TRAF   tumor necrosis factor receptor-associated factor  
Treg   regulatory T cells 
TRH   thyrotropin-releasing hormone 
TSP   thrombospondin  
VE-cadherin  vascular endothelial cadherin 
VEGF   vascular endothelial growth factor  
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Glioblastoma is the most frequent and aggressive intrinsic brain tumor in adults. 
Transforming growth factor (TGF)-β plays a major role in the malignant phenotype 
of glioblastoma and has been linked to migration and invasiveness of tumor cells 
and angiogenesis. Beyond it exerts an immunosuppressive action and sustains the 
stemness properties and the tumorigenicity of glioma-initiating cells (GIC). 
TGF-β is synthesized as a precursor molecule and is stored in an inactive, latent 
complex in the extracellular matrix (ECM). Different molecules are involved in the 
processing, secretion and release of the mature form of TGF-β from latent 
complexes. 
The precursor form, pro-TGF-β, is proteolytically processed to the mature form by 
proprotein convertases subtilisin/kexin (PCSK). The studies performed for this 
thesis show that furin is unique among the PCSK in being highly expressed in GIC 
and that furin is the main enzyme responsible for pro-TGF-β1 and pro-TGF-β2 
processing in GIC. Notably, pro-TGF-β processing takes place to a greater extent 
extracellularly, qualifying furin as an extracellular regulator of TGF-β signaling and 
as a potential therapeutic target to counteract TGF-β in GIC. Also, TGF-β2 controls 
furin levels and activity in GIC. Indeed, TGF-β2 induces furin expression in an 
activin-receptor like kinase (ALK)-5-dependent and SMAD-independent manner, 
involving members of the extracellular signal-regulated kinase/mitogen activated 
protein kinase (ERK/MAPK) pathway. Specifically, our results uncover a role for 
ERK1 in regulating basal furin levels and in supporting a self-sustaining loop for high 
TGF-β activity in GIC. Our data suggest that ERK1 blockade may be a potential 
therapeutic strategy to inhibit TGF-β in GIC. 
The extracellular environment and in particular different components of the ECM 
such as fibronectin (FN) and fibrillin are involved in the control of TGF-β latency. In 
glioblastoma, FN and the two alternative FN splice isoforms containing the extra-
domain A (EDA), EDA+FN, and extra-domain B (EDB), EDB+FN, are highly up-
regulated around tumor vasculature. TGF-β modulates the activation state of 
endothelial cells, regulating angiogenesis and endothelial cells plasticity. Here we 
show that TGF-β induces EDA+FN and EDB+FN in endothelial cells. Beyond, FN 
controls the TGF-β superfamily signaling pathway in endothelial cells, by specifically 
up-regulating the SMAD1,5 signaling branch via the EDA and EDB domains. This 
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suggests a positive feedback loop of TGF-β and EDA+FN/EDB+FN in endothelial 
cells with EDA+FN and EDB+FN maintaining TGF-β superfamily-dependent 
SMAD1,5 signaling. Further investigation in glioblastoma-derived endothelial cells 
as well as functional studies may reveal whether EDA+FN and EDB+FN may serve 







Das Glioblastom ist der häufigste bösartige, hirneigene Tumor beim Erwachsenen. 
Bei der Pathogenese des Glioblastoms spielt der Botenstoff «transforming growth 
factor» (TGF)-β eine wichtige Rolle, da er das infiltrative Wachstum des Tumors und 
die Bildung von Blutgefäßen fördert und Tumorstammzellen, die sogenannten 
Gliom-initiierenden Zellen (GIC), am Leben erhält. Ebenso schützt das von 
Gliomzellen sezernierte TGF-β den Tumor vor körpereigenen 
Abwehrmechanismen.  
TGF-β wird als Vorläuferprotein gebildet und in der extrazellulären Matrix (ECM) in 
einem Komplex in einer inaktiven Form gelagert. Verschiedene Moleküle sind an 
der Prozessierung, Sezernierung und Freisetzung der prozessierten 
beziehungsweise aktiven Form aus inaktiven Komplexen beteiligt.  
Das Vorläuferprotein, pro-TGF-β, wird durch die Enzymfamilie der 
Proproteinkonvertasen vom subtilisin/kexin-Typ (PCSK) prozessiert. In dieser Arbeit 
wurde gezeigt, dass Furin unter den PCSK in GIC insofern einzigartig ist, als dass 
es von GIC stark exprimiert wird und unter den PCSK hauptsächlich für die 
Prozessierung von pro-TGF-β1 und pro-TGF-β2 verantwortlich ist. 
Bemerkenswerterweise zeigten die Studien auch, dass die Prozessierung von pro-
TGF-β zu einem grossen Teil in der ECM stattfindet. Dies macht Furin zu einem 
extrazellulären Regulator der TGF-β-Signaltransduktion und einem möglichen 
therapeutischen Zielprotein, das TGF-β-System in GIC zu hemmen. Im Laufe dieser 
Arbeit wurde zudem gezeigt, dass TGF-β2 die Furinspiegel und -aktivität in GIC 
kontrolliert. TGF-β2 induziert die Furinexpression über den TGF-β-Rezeptor «activin 
like kinase» (ALK)-5, jedoch unabhängig von den Smad-
Signaltransduktionsmolekülen. In der Tat erfolgt die TGF-β2-induzierte 
Furinexpression in einer ALK-5-abhängigen und SMAD-unabhängigen Weise unter 
Beteiligung von Mitgliedern des «extracellular signal-regulated kinase/mitogen 
activated protein kinase (ERK/MAPK)» Signaltransduktionswegs. Die 
Untersuchungen der vorliegenden Arbeit identifizierten insbesondere die Isoform 
ERK1 als Regulator der basalen und TGF-β-induzierten Furinexpresion. Insgesamt 
illustrieren diese Ergebnisse, dass ERK1 eine wichtige Rolle bei der positiven 
Regulation dieses selbsterhaltenden Kreislaufs hoher TGF-β-Aktivität spielt und 
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somit die spezifische ERK1-Blockade eine mögliche Strategie der TGF-β-Inhibition 
in GIC darstellen könnte.  
Das extrazelluläre Milieu und im Besonderen verschiedene Komponenten der ECM 
wie die Proteine Fibronektin und Fibrillin kontrollieren die TGF-β-Freisetzung aus 
inaktiven TGF-β-Komplexen. Beim Glioblastom sind Fibronektin (FN) und die 
beiden alternativen FN-Spleißvarianten, die “extra-domain A” (EDA) und die «extra-
domain B» (EDB) enthalten, EDA+FN und EDB+FN, in den Gefäßstrukturen des 
Tumors sehr stark exprimiert. TGF-β beeinflusst die Aktivierung von Endothelzellen, 
indem es Angiogenese und Plastizität von Endothelzellen reguliert. In dieser Arbeit 
wurde gezeigt, dass TGF-β EDA+FN und EDB+FN in Endothelzellen induziert. 
Darüber hinaus kontrolliert FN den Signaltransduktionsweg der TGF-β-
Superfamilie, indem es in den Endothelzellen über die EDA- und EDB-Domänen die 
SMAD1,5-Signaltransduktion positiv reguliert. Das legt einen positiven, 
selbsterhaltenden Kreislauf von TGF-β und EDA+FN/EDB+FN in Endothelzellen 
nahe. Weitere Untersuchungen in direkt von Glioblastomen gewonnenen 
Endothelzellen sowie funktionelle Studien werden zeigen, ob sich EDA+FN und 










Gliomas are the most common primary tumors of the central nervous system (CNS) 
in the adult. Glioblastoma, representing approximately half of the newly diagnosed 
gliomas, is the most aggressive brain tumor and has a median patient survival of 
14-17 months (Reifenberger et al., 2016).  
The cell of origin of gliomas is still controversial. Several studies in animal models 
suggest that different cell types can generate gliomas including neural stem cells 
and oligodendroglial progenitor cells (Alcantara Llaguno and Parada, 2016). 
According to the most recent World Health Organization (WHO) Classification of 
Tumors of the CNS published in 2016, gliomas are diagnosed following an 
integrated approach which combines the histological classification, which was the 
only criterion used in the previous classification of 2007, with molecular information 
(Louis et al., 2016; Reifenberger et al., 2016). This approach allows a more precise 
classification of gliomas with improved prediction of clinical outcome and treatment 
response. 
According to the new classification, the first layer of classification is based on the 
histological tumor type considering cytological features and expression of lineage-
associated proteins of astrocytic or oligodendroglial cells (Alcantara Llaguno and 
Parada, 2016). The second layer is represented by tumor grading according to the 
WHO definition taking into account the degree of cell anaplasia. Circumscribed and 
low-proliferative lesions are assigned grade I. Grade II lesions are low proliferative, 
but show cytological atypia and are infiltrative. Grade III tumors show 
hypercellularity, nuclear atypia, and high mitotic activity. Grade IV tumors show 
characteristics of grade III tumors, with the additional features of microvascular 
proliferation and necrosis (Louis et al., 2007; Wen and Kesari, 2008). The third layer 
of classification is based on the molecular characteristics of the tumor. Several 
genetic and epigenetic alterations have been identified in gliomas (Parsons et al., 
2008; Verhaak et al., 2010; Brennan et al., 2013). Large-scale genomic and 
transcriptomic profiling of gliomas has been realized also in the context of 
international networks like “The Cancer Genome Atlas (TCGA)” (Cancer Genome 
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Atlas Research, 2008) and the “International Cancer Genome Consortium” (ICGC) 
(International Cancer Genome et al., 2010). Some of these molecular alterations 
are used for the diagnosis of gliomas (Figure 1) or as predictive biomarkers of 
patient response to therapy and are described in the following. 
 
- IDH. The determination of isocitrate dehydrogenase 1 or 2 (IDH1/2) status 
represents the first layer of the molecular diagnosis (Figure 1). IDH status is first 
assessed by immunohistochemistry with an antibody specific for the most common 
IDH mutation in gliomas (IDH1-R132H). Tumors which are negative by 
immunohistochemistry undergo molecular testing in order to exclude the presence 
of other IDH1/2 mutations. IDH mutation is one of the earliest event occurring in 
gliomas (Suzuki et al., 2015) and identifies biologically different tumors with a 
different clinical behavior and improved prognosis when compared to IDH-wild-type 
gliomas (Parsons et al., 2008; Sanson et al., 2009; Yan et al., 2009). Mutated IDH 
proteins acquire the ability to convert α-ketoglutarate (α-KG) into D-2-
hydroxyglutarate (D-2-HG) (Dang et al., 2009). D-2-HG acts as a competitive 
inhibitor of α-KG-dependent dioxygenases, including some DNA and histone 
demethylases (Xu et al., 2011). This results in an increase in DNA and histone 
methylation leading to the hypermethylation of CpG islands and a glioma phenotype 
known as "glioma CpG-island methylator phenotype" (G-CIMP) (Noushmehr et al., 
2010; Liu et al., 2012). 
 
- ATRX. After the definition of the IDH 1/2 status, the molecular diagnosis may 
proceed with the immunohistochemical assessment of the nuclear retention or loss 
of α-thalassemia/mental retardation syndrome X-linked (ATRX) transcription factor. 
ATRX is involved in chromatin remodeling (Liu et al., 2012; Watson et al., 2015). 
 
- 1p/19q. The combined loss of genetic material from the p arm of chromosome 1 
and from the q arm of chromosome 19, which is the consequence of an unbalanced 
t(1; 19) (q10; p10) translocation and known as 1p/19q co-deletion, is assessed in 
patients with histological diagnosis of diffuse astrocytic or oligodendroglial gliomas 
with IDH-mutant status and nuclear ATRX retention. The 1p/19q codeletion defines 
oligodendrogliomas, and is used as a biomarker to predict benefit from upfront 
radiotherapy (RT) and chemotherapy with procarbazine, CCNU and vincristine 
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(PCV) compared to RT alone in patients with anaplastic gliomas (Cairncross et al., 
2013; van den Bent et al., 2013). 
 
- H3-K27M-mutant. The K27M mutation in the histone H3.3 gene characterizes 
gliomas developing in midline structures (thalamus, brainstem, and spinal cord) 
(Louis et al., 2016).  
 
- MGMT. 06-methylguanine-DNA methyltransferase (MGMT) is a DNA repair 
protein. It repairs DNA alkylation induced by alkylating agents like temozolomide 
(TMZ). Glioblastoma with hypermethylated MGMT promoter show reduced levels of 
MGMT protein, translating into a reduced ability of DNA repair. The MGMT status is 
usually homogenous within different tumor areas and is maintained at tumor 
recurrence. In patients with IDH-wild-type status, MGMT promoter hypermethylation 
is a predictor of benefit from TMZ treatment and increased survival (Hegi et al., 
2005; Wick et al., 2012). 
 
According to the new classification, glioblastomas are divided into two categories 
based on their IDH status: IDH-wild-type and IDH-mutant glioblastomas. IDH–wild-
type glioblastomas encompass ~ 90% of cases, and clinically they correspond to de 
novo glioblastomas with a predominance in patients older than 50 years. IDH-
mutant glioblastomas cover the remaining ~ 10% and correspond to glioblastomas 
arising in younger patients and derived from lower grade diffuse gliomas 





Figure 1. Diffuse glioma diagnosis according to the 2016 World Health Organization 
Classification of Tumors of the Central Nervous System. The starting point of diffuse glioma 
diagnosis is the histopathological typing and grading into grade II/III gliomas and grade IV 
glioma/glioblastoma. The diagnosis than proceeds with the analysis of IDH1/2 status, ATRX nuclear 
loss, chromosome 1p/19q codeletion and H3-K27M mutations. The integration of the 
histopathological diagnosis with the molecular information leads to the final diagnosis. IDH1/2, 
isocitrate dehydrogenase 1 or 2; ATRX, α-thalassemia/mental retardation syndrome X-linked; H3-
K27M, histone 3 K27M mutation (adapted from Reifenberger et al. 2016). 
 
 
3.1.2 Molecular pathways altered in glioblastoma 
In addition to the genetic and epigenetic alterations described above, many other 
molecular lesions have been identified in gliomas (Cancer Genome Atlas Research, 
2008; Parsons et al., 2008; Brennan et al., 2009; International Cancer Genome et 
al., 2010; Verhaak et al., 2010). Macroscopic genomic alterations with the loss of 
chromosome 10 and the gain of chromosome 7 are common in IDH-wild-type 
glioblastomas (Aldape et al., 2015). Some frequent genomic alterations affect genes 
encoding for tumor suppressor proteins such as p53 (Watanabe et al., 2001; Cancer 
Genome Atlas Research, 2008), retinoblastoma (Rb) (Henson et al., 1994; 
Watanabe et al., 2001; Cancer Genome Atlas Research, 2008) and cyclin-
dependent kinase Inhibitor 2A (CDKN2A) (Weber et al., 2007). In particular, TP53 
is mutated in 81% of IDH-mutant glioblastomas. In addition to mutations or 
alterations in the copy number of these genes, the reduced activity of p53 and Rb 
signaling pathways can also be the consequence of gene amplification events 
leading to increased levels of p53 and Rb repressors, like cycling-dependent kinase 
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(CDK)4 and mouse double minute (MDM)2 (Cancer Genome Atlas Research, 
2008).  
The second group of common alterations in glioblastoma involves receptor tyrosine 
kinases/RAS/phosphatidylinositol 3-kinase (RTK/RAS/PI3K) signaling pathways 
(McBride et al., 2010; Verhaak et al., 2010; Snuderl et al., 2011). The most 
frequently altered RTK in glioblastoma are epidermal growth factor receptor 
(EGFR), platelet-derived growth factor receptor alpha (PDGFRA) and MET. Around 
40% of IDH–wild-type glioblastoma show EGFR amplification. Also, 50% of tumors 
showing EGFR amplification express a mutated and constitutively active form of 
EGFR known as EGFRvIII (Frederick et al., 2000; Lee et al., 2006; Hegi et al., 2012; 
Liu et al., 2015). The EGFRvIII variant has attracted attention since the mutation 
leading to EGFRvIII generates a novel epitope that may be potentially used as 
tumor-associated antigen for vaccination therapeutic approaches (Reifenberger et 
al., 2016). The increase in PDGFR signaling is usually associated with PDGFRA 
amplification (Verhaak et al., 2010) and promotes proliferation of tumor cells. 
Amplification of MET has been attributed an important role in gliomagenesis as well 
(Parsons et al., 2008). Downstream to RTK, mutations in the signaling pathways of 
RAS and PI3K are common and include: 1) mutations in the gene encoding for PI3K 
(Suzuki et al., 2015); 2) deletions, mutations or epigenetic alterations affecting the 
gene encoding for the inhibitor of PI3K pathway, phosphatase and tensin homolog 
(PTEN) (Wiencke et al., 2007; Huse et al., 2009), which are present in 24% of IDH-
wild-type glioblastomas; 3) mutations in the gene of neurofibromin 1 (NF1) (Cancer 
Genome Atlas Research, 2008; Parsons et al., 2008; Verhaak et al., 2010), a 
negative regulator of RAS and mammalian target of rapamycin (mTOR) signaling 
pathways. In some glioblastoma the V600E mutation in B-Raf proto-oncogene 
serine/threonine kinase (BRAF) is detected (Suzuki et al., 2015). Finally, another 
frequent genetic alteration affects the telomerase reverse transcriptase (TERT) 
gene (Arita et al., 2013; Killela et al., 2013; Koelsche et al., 2013). Mutations in the 
TERT promoter lead to aberrant expression of TERT and are detected in 72% IDH–
wild-type and 26% IDH-mutant glioblastomas (Aldape et al., 2015) and present in > 




3.1.3 Diagnosis and therapy 
The standard diagnostic technique for patients with suspected tumor brains is 
magnetic resonance imaging (MRI). In MRI gliomas appear as heterogeneously 
enhancing masses surrounded by edema. In glioblastomas, edema is usually more 
pronounced than in the other gliomas, and the lesions show central necrosis (Wen 
and Kesari, 2008; Weller et al., 2014). 
Surgical tumor resection as feasible is the primary treatment for all gliomas. For non-
invasive tumors like pilocytic astrocytoma, pleomorphic xanthoastrocytoma (PXA) 
and subependymal giant cell astrocytoma (SEGA) surgery is often curative 
(Reifenberger et al., 2016). For all the other gliomas, additional post-surgery 
therapies are applied. The type of treatment depends on the tumor type, the 
expression of specific biomarkers and patient characteristics like age and clinical 
performance (Weller et al., 2014; Reifenberger et al., 2016). The treatment 
approaches currently adopted for gliomas therapy are summarized in figure 2. For 
glioblastoma patients, the standard of care following surgery consists in RT, a total 
dose of 60 Gy divided into 30 fractions, in combination with daily administration of 
TMZ. After the combined RT/TMZ treatment, patients receive six cycles of 






Figure 2. Standard post-surgery treatments in major glioma entities. a. Post-surgery treatment 
in IDH-mutant adult gliomas. b. Post-surgery treatment in IDH–wild-type adult gliomas. c. Post-
surgery treatment in pediatric gliomas. RT, radiotherapy; PCV, procarbazine, CCNU, vincristine; 





3.2. GLIOMA INITIATING CELLS 
 
3.2.1. Cancer stem cells 
Somatic stem cells are defined as rare, self-renewing cells residing in specific niches 
in adult tissues. Throughout asymmetric division they generate transient amplifying 
cells, which in turn create lineage-restricted progeny capable of giving rise to 
terminally differentiated cells (Watt and Hogan, 2000). 
According to the cancer stem cell hypothesis tumors contain a small distinct 
population of tumor cells, the so-called cancer stem cells (CSC), sharing several 
properties with somatic stem cells including self-renewal, multipotency and 
asymmetric division and which would be responsible for tumor initiation and 
recurrence (Reya et al., 2001; Nassar and Blanpain, 2016). The CSC hypothesis 
thus implies a hierarchical model of tumors with the CSC as a small number of cells 
at their apex, giving rise to populations of tumor cells with different degrees of 
differentiation and limited proliferative ability (Reya et al., 2001; Nassar and 
Blanpain, 2016). 
The existence of CSC was first suggested in 1971 by Park and colleagues who 
described the isolation of mouse myeloma tumor stem cells (Park et al., 1971). The 
first report on human CSC from Lapidot and colleagues in 1994 showed that a single 
tumor cell isolated from acute myeloid leukemia (AML) patients was able to initiate 
AML in mice following transplantation (Lapidot et al., 1994). After extensive 
documentation in hematological neoplasms, the existence of CSC was also 
suggested in solid cancers (Reya et al., 2001). The investigation of the potential 
existence of brain CSC started after the first isolation of neural stem and progenitor 
cells (NSPC) (Uchida et al., 2000). Indeed, brain CSC, sharing characteristics with 
NSPC, were first described in anaplastic astrocytoma and recurrent glioblastoma 
(Ignatova et al., 2002), in medulloblastoma (Hemmati et al., 2003; Singh et al., 2003) 
pilocytic astrocytoma, ependymoma, ganglioma (Singh et al., 2003) and again 
glioblastoma (Singh et al., 2003; Galli et al., 2004). 
 
 
3.2.2. Glioma stem cells/glioma-initiating cells  
According to the CSC theory of cancer, CSC would be less sensitive to therapy 
compared to the bulk tumor and would be responsible for tumor relapse (Reya et 
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al., 2001; Nassar and Blanpain, 2016). Several studies demonstrated the glioma 
CSC resistance to both chemotherapy and irradiation, pointing towards the 
necessity to specifically characterize this cell population in vitro and in vivo (Bao et 
al., 2006a; Wang et al., 2010a; Venere et al., 2014). 
Several methods have been proposed for the enrichment of glioma CSC. One of the 
most commonly pursued approaches is based on the use of CSC markers. CSC, 
like somatic stem cells, express stem cell markers. Many glioma CSC stem markers 
are transcription factors fundamental also for NSPC functions including SRY-box 
containing gene (SOX)2, Nanog, oligodendrocyte lineage transcription factor 
(OLIG)2, Myc, Musashi1, Nestin, and BMI1 (Lathia et al., 2015). In addition to these 
intracellular markers, glioma CSC also express cell surface markers that can be 
used for their enrichment including CD133, CD15, CD44, L1 cell adhesion molecule 
(L1CAM) and A2B5 (Lathia et al., 2015). CD133 (Prominin-1), a cholesterol-binding 
glycoprotein expressed on neural stem cells with unknown functions, was the first 
cell surface marker proposed and is still the most commonly used marker to enrich 
glioma stem cells (Singh et al., 2003). Meanwhile diverse studies have indicated 
that CD133 should be used carefully since only the glycosylated surface CD133 
molecule, corresponding to the antigen AC133, is CSC-specific and not CD133 
expression per se. Indeed CD133 mRNA levels do not correlate with stemness 
(Kemper et al., 2010). Besides, other studies demonstrated the presence of AC133-
negative CSC in gliomas (Beier et al., 2007) or showed that AC133-negative cells 
can generate AC133-positve cells (Chen et al.; Wang et al., 2008), underling the 
plasticity between the two cell populations. 
Overall, the expression of stemness markers is considered not sufficient to define a 
tumor cell a cancer stem cell, instead a functional validation is needed (Figure 3). 
Compulsory functional characteristics include sustained self-renewal, persistent 
proliferation and the capacity, when implanted orthotopically in vivo, to generate 
tumors. Based on their behavior in vivo tumor cells with stemness properties are 
defined according to the following (Lathia et al., 2015): 
- Cancer stem cells/cancer stem-like cells (CSC): defined as a self-renewing cell 
with the ability to give rise to differentiated progeny. Functionally characterized by 
the capacity of generating a tumor upon secondary transplantation that contains 
cellular heterogeneity and progeny with varying degrees of self-renewal capacity 
(Lathia et al., 2015); 
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- Cancer-initiating cells (glioma-initiating cells (GIC), in the case of glioma): defined 
as cells with the ability to initiate a tumor upon transplantation. Functionally 
characterized by the capacity of generating a tumor upon secondary transplantation 
(Lathia et al., 2015); 
- Cancer-propagating cell: defined as cells with the ability to propagate tumor upon 
transplantation. Functionally characterized by the capacity of propagating a tumor 
upon serial transplantation (Lathia et al., 2015). 
 
 
Figure 3. Characteristics of cancer stem cells (CSC) and their functional validation. CSC as 
somatic stem cells are usually very rare, express stem cell markers and have the capacity of 
generating differentiated cells of different lineage. Functionally, CSC are defined as cells with self-
renewal capacity, characterized by continuous proliferation and by the ability to generate, after 
orthotopically implantation in vivo of a reduced number of cells, tumors recapitulating the tumor of 
origin (adapted from Lathia et al., 2015.).  
 
Alternative methods to the use of stem cell markers for enrichment of glioma CSC 
include the selection of specific culture conditions which are commonly used for the 
culture of neural stem cells, i.e. the use of neurobasal serum-free medium 
containing epidermal growth factor (EGF) and fibroblasts growth factor (FGF) 
(Lathia et al., 2015). In vitro assays such as sphere formation assays may be used 
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to evaluate proliferation and self-renewal and in case this is done with limiting 
dilution also to determine the frequency of stem cells. Nonetheless, the golden 
standard assay to functionally validate CSC is represented by the determination of 
the ability to generate, after orthotopic implantation of a limited number of cells, 
tumors in vivo morphologically and immunohistochemically recapitulating the tumor 
of origin and thus showing heterogeneity and cellular hierarchy. Indeed, 
glioblastoma show high intratumoral heterogeneity and are characterized by the 
presence of different niches enriched in cells with specific properties, including self-
renewal, high proliferation, radio-resistance and adaption to hypoxic conditions 
(Patel et al., 2014). 
 
 
3.2.3. GIC and their microenvironment 
Somatic stem cells reside in specific niches within tissues with the niche controlling 
the equilibrium between stem cell quiescence and tissue regeneration (Moore and 
Lemischka, 2006). In the brain, neural stem cells are located close to blood vessels 
in two main niches in the subventricular zone and in the subgranular zone (Taupin, 
2006). Accordingly, CSC are not casually interspersed in tumors but reside in 
niches. In glioblastoma two main niches have been identified, i.e. the perivascular 
(Calabrese et al., 2007) and the hypoxic (Seidel et al., 2010) niches. Concerning the 
perivascular niche, some studies suggested that CSC can also become an integral 
part of the vasculature it-self, by trans-differentiating into endothelial cells (Ricci-
Vitiani et al., 2010; Wang et al., 2010b) or pericytes (Cheng et al., 2013).  
Several soluble factors present in the niche and more generally in the 
microenvironment of glioblastoma as well as cell–to-cell communications lead to the 
activation of signaling pathways in CSC that contribute to the maintenance of their 
undifferentiated state and promote their proliferation. Some of these signaling 
pathways are also involved in the maintenance of NSPC and may include sonic 
hedgehog, Notch, nuclear factor-κB (NF-kB), Wnt, PI3K/AKT and nitric oxide 
signaling (Lathia et al., 2015). Also, glioma CSC survival and self-renewal is 
influenced by different growth factors and in particular platelet-derived growth factor 
(PDGF), EGF, and transforming growth factor-β (TGF-β) (Lathia et al., 2015). 
The communication between glioma CSC and the cells present in the niche and the 
microenvironment is bi-directional. This aspect has been investigated mainly with 
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regard to the glioma CSC-endothelial cells cross-talk. On the one hand, different 
studies have attested a role for endothelial cells in regulating the stemness of CSC 
residing in perivascular niches (Lathia et al., 2015). Moreover, a role for the 
perivascular niche in protecting CSC after radiation treatment has also been 
suggested (Bao et al., 2006a). On the other hand, glioma CSC express elevated 
levels of vascular endothelial growth factor (VEGF) (Bao et al., 2006b) and can 
induce endothelial cells to produce VEGF and brain-derived neurotrophic factor 
(BDNF) (Li et al., 2006) promoting tumor angiogenesis. In the perivascular niche, 
glioma CSC come in contact also with cells belonging to the immune system. 
Immunosuppressive properties have been attributed to glioma CSC, dependent on 
both cell-cell contact and on the release of soluble factors. Glioma CSC can induce 
regulatory T (Treg) cells and on the other side inhibit cytotoxic T-lymphocyte 
proliferation and activation and induce their apoptosis (Di Tomaso et al., 2010; Wei 
et al., 2010). Also, by releasing interleukin (IL)-10 and TGF-β, glioma CSC can 
promote the polarization of tumor-associated macrophages towards a pro-
tumorigenic phenotype (Wu et al., 2010).  
Glioma CSC show high ability to adapt to stressful microenvironmental conditions, 
including hypoxia and restriction of nutrients. Different studies illustrated the central 
role played by both metabolic and epigenetic reprogramming in this context. For 
example, it has been shown that glioma CSC express the high glucose affinity 
neuronal glucose transporter (Glut)3 to preferentially take up glucose and resist to 
nutrition restriction (Flavahan et al., 2013). In another study, it has been 
demonstrated that glioblastoma CSC, through epigenetic reprograming, acquire an 
increased capacity to take up iron from the environment (Schonberg et al., 2015). 
Recently, it has been demonstrated how, by chromatin remodeling, glioma CSC 
enter, in a reversible manner, in a slow-cycling state that allows them to resist to 





3.3. TRANSFORMING GROWTH FACTOR (TGF)-β 
 
3.3.1. TGF-β superfamily 
TGF-β is the prototype of an ancient superfamily of growth and differentiation 
factors, emerging with the first TGF–β-like growth factor during the early evolution 
of the deuterostomes (Burt and Law, 1994; Herpin et al., 2004; Robertson and 
Rifkin, 2013). Members of the TGF-β superfamily have been identified in extremely 
simple metazoans like sponges (Adamska et al., 2007) and ctenophores (Pang et 
al., 2011). Evolutionary studies based on sequences belonging to a broad range of 
species revealed that TGF-β superfamily ligands as well as their receptors and 
downstream mediators are highly conserved during evolution and led to the 
identification of several subfamilies (Burt and Law, 1994; Robertson and Rifkin, 
2013). Based on structure similarities TGF-β superfamily ligands can be divided into 
TGF-β, bone morphogenetic proteins (BMP) and activins/inhibins. Concerning the 
three TGF-β isoforms TGF-β1, TGF-β2 and TGF-β3, TGF-β2 and TGF-β3 cluster 
to a separate sub-tree when compared to TGF-β1, suggesting that these two 
isoforms emerged as a consequence of a second gene duplication event occurring 
later during evolution (Robertson and Rifkin, 2013). In human the TGF-β superfamily 
consists of 30 members identified so far including the three TGF-β isoforms, ten 
BMP, eleven growth differentiation factors (GDF), four activin β-chains/inhibin, the 
anti-Muellerian hormone (AMH) and nodal (Figure 4).  
TGF-β superfamily members play fundamental roles in embryogenesis and tissue 
homeostasis (Wu and Hill, 2009). Concerning the three TGF-β isoforms, knockout 
mice revealed their roles during embryogenesis. TGF-β1 knockout mice show 
defects in hematopoiesis and vasculogenesis and die few weeks after birth because 
of severe inflammation affecting different organs (Kulkarni et al., 1995). Around 60% 
of TGF-β2 knockout mice die during or soon after birth because of defects affecting 
several organs and tissues and mainly the heart, the skeleton and the kidney 
(Sanford et al., 1997). TGF-β3 knockout mice die within few hours after birth mainly 
because of defective lung development and cleft palate (Kaartinen et al., 1995). The 
different phenotypes of the three types of knockout mice suggest that, even if TGF-
β isoforms show similar effects in vitro, they have non redundant functions in vivo, 
which are only in part associated to their different spatial-temporal expression 
pattern (Robertson and Rifkin, 2013). In addition to the fundamental role played by 
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TGF-β in development TGF-β signaling is important for the maintenance of tissue 
homeostasis and the deregulation of its activity is associated with different 
pathological conditions (Blobe et al., 2000) including inflammation (Han et al., 2012), 
fibrosis (Meng et al., 2016) and cancers (Massague, 2008). 
 
 
Figure 4. Phylogenetic tree of TGF-β superfamily ligands. Phylogenetic tree of TGF-β 
superfamily ligands obtained by protein alignment in human and Drosophila melanogaster. Human 
sequences are in black; Drosophila melanogaster sequences are in grey (adapted from Schmierer 
and Hill 2007). 
 
 
3.3.2. TGF-β processing, secretion, and activation 
TGF-β synthesis, processing, secretion, and activation is a multistep process which 
involves different enzymes/regulatory molecules (Figure 5). 
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TGF-β is synthesized as a pre-pro-protein, including a signal peptide, an amino-
terminal pro-domain and the carboxy-terminal TGF-β family polypeptide (Figure 5a, 
1). After removal of the signal peptide, pro-TGF-β covalently homodimerizes in the 
endoplasmic reticulum (Figure 5a, 2). In the trans-Golgi network TGF-β is then 
processed by endoproteases belonging to the family of PSKC (Constam, 2014). The 
two products of this proteolytic process, i.e. a covalent dimer of mature TGF-β and 
a covalent dimer of the pro-domain, known as latency associated peptide (LAP), 
form a non-covalent complex known as the small latent complex (SLC) (Figure 5a, 
3). The SLC usually forms an inter-molecular disulfide bond with a single molecule 
belonging to the family of the latent TGF-β binding proteins (LTBP) (Figure 5a, 4) 
(Oklu et al., 2011). Binding to LTBP favors pro-TGF-β folding and, at a later step, 
promotes TGF-β secretion. The SLC and LTBP form the so-called large latent 
complex (LLC). The LLC is released and accumulated in the extracellular matrix 
(ECM), where it interacts with ECM molecules through LTBP (Figure 5a, 4) 
(Robertson and Rifkin, 2013; Robertson et al., 2015). Specifically, the amino-
terminal regions of LTBP 1,2 and 4 interact with fibronectin and the carboxy-
terminus of LTBP 1,2 and 4 interacts with fibrillin (Robertson and Rifkin, 2013; 
Robertson et al., 2015). In this ECM-associated format mature TGF-β is inactive. To 
be active it must be released from its latent ECM-associated form. The importance 
of the ECM in controlling the activation state of TGF-β is exemplified by pathological 
conditions such as the Marfan syndrome, where a mutation in the fibrillin gene is 
associated to an excessive activation of TGF-β (Dietz et al., 2005). Besides, mice 
lacking the fibronectin isoform containing the extra-domain A show reduced TGF-
β1 activation (Muro et al., 2008; White et al., 2008).  
Several mechanisms allowing the release of TGF-β from the latent ECM-associated 
complex have been described, and these involve integrins (Wipff and Hinz, 2008), 
proteases and physicochemical factors (Figure 5b) (Robertson and Rifkin, 2013). 
The integrins αvβ6 and αvβ8 bind to the LAP and are involved in TGF-β release 
from the ECM via two different mechanisms. The interaction between integrin αvβ6 
and LTBP allows the transmission of traction forces from the cell surface and the 
ECM to the LLC leading to the release of active TGF-β (Annes et al., 2002; Annes 
et al., 2004; Fontana et al., 2005). Integrins such as αvβ8 recruit matrix 
metalloproteases (MMP) on LLC promoting the cleavage of the LAP and the release 
of active TGF-β (Mu et al., 2002). Concerning proteases, plasmin is the most studied 
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enzyme involved in TGF-β activation (Lyons et al., 1990). Other proteases include 
the metalloproteases MMP2 and MMP9 (Yu and Stamenkovic, 2000) and BMP1 
(Ge and Greenspan, 2006), kallikreins, calpain (Abe et al., 1998) and cathepsin-D 
(Jenkins, 2008). Also, de-glycosidase may facilitate TGF-β activation by 
deglycosylating the LAP and favoring the consequent proteolytic cleavage of the 
LAP inducing the release of active TGF-β (Miyazono and Heldin, 1989). Other 
proteins involved in TGF-β activation include thrombospondin 1 (TSP1), F-
spondin/spondin-1 and neuropilin (NRP) (Robertson and Rifkin, 2013). Finally, 
physicochemical factors such as UVB and ionizing radiation, reactive oxygen 
species, heat and pH extremes can activate TGF-β (Robertson and Rifkin, 2013).  
 
 
Figure 5. Pictogram of TGF-β synthesis, secretion and activation. The depicted molecules and 
steps are described in the text. Once released mature TGF-β is active and can bind to TGF-β 
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receptors (adapted from ten Dijke P. & Arthur E. M. Extracellular control of TGF-β signaling in 
vascular development and disease. Nature Reviews Molecular Cell Biology 2007, 8: 857-869). 
 
 
3.3.3. TGF-β signaling 
TGF-β superfamily ligands signal to the cell through binding to transmembrane 
receptors belonging to two functional classes, the so called type I and type II 
receptors. In human, seven type I and five type II receptors have been identified, 
i.e. type I/activin-receptor like kinase (ALK) 1-7 and the type II receptors TGFβRII, 
ACTRII, ACTRIIB, BMPRII and AMHRII (Schmierer and Hill, 2007). TGF-β binds 
mainly to the type I receptor ALK-5 and, with lower affinity, to the receptor ALK-1 
and exclusively to the type II receptor TGFβRII. Both type I and type II receptors are 
Ser/Thr protein kinases, being the only transmembrane Ser/Thr kinases described 
so far. Ligand binding leads to the assembly of the tetrameric TGFβR complex made 
of a dimer of type I receptors and a dimer of type II receptors (Figure 6). Upon ligand 
binding, type II receptors phosphorylate type I receptors in their Gly-Ser-rich 
juxtamembrane domain. The phosphorylated Gly-Ser-rich domain recruits the 
receptor-regulated SMAD proteins (R-SMAD) SMAD1,2,3,5 and 8, which are in turn 
phosphorylated by type I receptors (Schmierer and Hill, 2007). The receptors ALK-
4, ALK-5 and ALK-7 bind to and phosphorylate the R-SMAD2 and 3 and the 
receptors ALK-1, ALK-3 and ALK-6 bind to and phosphorylate R-SMAD1,5 and 8 
(Schmierer and Hill, 2007). Since the main type I receptor of TGF-β is ALK-5, TGF-
β signaling mainly results in the phosphorylation of SMAD2 and 3. Nonetheless, in 
endothelial cells expressing both ALK-5 and the endothelial-specific receptor ALK-
1, TGF-β can recruit both the ALK-5 and ALK-1 receptors in one complex and 
activate both the SMAD2,3 and SMAD1,5,8 branches (Goumans et al., 2003; Byfield 
and Roberts, 2004).  
Upon phosphorylation R-SMAD dimerize and bind to the common mediator SMAD4. 
In their inactive, dephosphorylated state, R-SMAD shuffle between the nucleus and 
the cytoplasm. Upon phosphorylation, dimerization and complex formation with 
SMAD4, R-SMAD/SMAD4 complexes accumulate in the nucleus to interact with 
transcription factors, co-activators, and co-repressors and bind to DNA. Thus, 
SMAD complexes regulate gene expression and also regulate chromatin-
remodeling and histone modifications by recruiting chromatin-remodeling and 
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histone-modifying enzymes (Schmierer and Hill, 2007). SMAD proteins consist of 
two conserved domains, known as mad homology (MH) domains 1 and 2, 
connected by a linker region. The MH1 domain is a DNA-harping binding domain 
that allows the direct interaction of SMAD with the DNA. DNA binding occurs at the 
SBE (SMAD-binding element) DNA motif (Schmierer and Hill, 2007). In the case of 
SMAD2, the MH1 domain contains a small insert that does not allow SMAD2 to 
interact directly with the DNA, thus SMAD2 binding to DNA requires its interaction 
with other DNA-binding proteins. The MH2 domain is responsible for inter-SMAD 
interaction and SMAD binding to receptors and transcription factors/regulators 
(Schmierer and Hill, 2007). The linker region can be phosphorylated by several 
kinases, including MAPK, glycogen synthase kinase-3β (GSK3B) and CDK with 
regulatory, both positive and negative, functions on SMAD activity (Schmierer and 
Hill, 2007). The activity of R-SMAD/SMAD4 complexes can be directly regulated by 
two additional SMAD proteins, SMAD6 and SMAD7, which have inhibitory functions 
(Schmierer and Hill, 2007). 
In addition to the SMAD-dependent TGF-β signaling, which is also called canonical 
TGF-β signaling, other signaling pathways, known in complex as non-
canonical/SMAD-independent signaling pathways have been described for the 
TGF-β superfamily (Figure 6) (Massague, 2012; Heldin and Moustakas, 2016; 
Zhang, 2017).  
The branches of the non-canonical signaling pathway are activated by diverse 
mechanisms. Some non-canonical signaling pathways are activated by type II 
receptors, others by type I receptors. The type II receptor TGFβRII is able to directly 
phosphorylate and activate the cell polarity regulator partitioning defective 6 (PAR6) 
which then recruits SMAD ubiquitylation regulatory factor (SMURF)1 and target 
RHOA guanosine triphosphate hydrolase (GTPase) at tight junctions consequently 
leading to the dissolution of tight junctions and polarized migration. This process is 
triggered by TGF-β in cells undergoing epithelial-to-mesenchymal transition (EMT) 
(Massague, 2012). Type I receptors can activate several non-SMAD signaling 
pathways, i.e. the p38, Jun amino-terminal kinase (JNK), inhibitor of kB kinase (IKK), 
mTOR, PI3K, ERK and RHO signaling pathways. Tumor necrosis factor receptor-
associated factor (TRAF)6 and SMAD7 directly bind to the receptor I leading to the 
activation of the TGF-β-activated kinase (TAK)1 which in turn phosphorylates and 
activates p38, JNK and IKK (Massague, 2012; Heldin and Moustakas, 2016; Zhang, 
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2017). Phosphorylated TGFβRI first recruits the adaptor protein Src-homology 
collagen (Shc) with the consequent recruitment of the adaptor protein Grb2 in 
complex with nucleotide exchange protein Sos1 and activation of RAS, which in 
turn, activates the ERK1/2 pathway (Heldin & Moustakas 2016). The molecular 
mechanism responsible for the activation of other signaling pathways, i.e. mTORC, 
PI3K and RHO is not known (Massague, 2012). 
 
 
Figure 6. TGF-β canonical and non-canonical signaling pathways. TGF-β binding to a tetrameric 
complex made of a dimer of TGF-β receptor I and a dimer of TGF receptor II leads to the 
phosphorylation of TGF-β receptor I and the consequent recruitment of SMAD2 and SMAD3. 
SMAD2, 3 are in turn phosphorylated and activated. Phosphorylated SMAD2 and SMAD3 form 
complexes with SMAD4 and translocate into the nucleus where they bind to the DNA and regulate 
gene expression. In addition to the SMAD pathway, TGF-β may activate other signaling pathways, 
known as non-SMAD pathways including p38, Jun amino-terminal kinase (JNK), extracellular-signal 
regulated kinase (ERK), phosphoinositide 3-kinase (PI3K)-AKT, and the RHO GTPase and CDC42 
signaling pathways (adapted from Ikushima and Miyazono 2010). 
 
Modulation of TGF-β superfamily signaling occurs on different levels. First, the 
canonical/SMAD-dependent and the non canonical/SMAD-independent signaling 
pathways cross-talk at different levels (Zhang, 2017). Further, TGF-β superfamily 
signaling can be modulated on the receptor level by several mechanisms based on 
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the interaction of the receptors with the coreceptors betaglycan/TGFβRIII, endoglin, 
cripto, CD109 and neuropilin, in concert with other cell surface molecules and 
receptors (Heldin and Moustakas, 2016). Finally, TGF-β receptors activity can be 
modulated by tuning their endocytosis (Heldin and Moustakas, 2016). 
The transcriptional response triggered by TGF-β superfamily ligands is strongly 
context-dependent (Figure 7). The first group of factors influencing the final cell 
response is represented by the relative abundance of molecules initiating and 
controlling the process of signal transduction, i.e., the levels of different TGF-β 
superfamily ligands, receptors, co-receptors and ligand-traps (Massague, 2012). 
Further downstream, the abundance of the inhibitory SMAD proteins and the type 
and intensity of cross-talk between the SMAD and non-SMAD signaling pathways 
affect SMAD activity (Massague, 2012). A second factor influencing the final cell 
response is represented by the expression, in a given cell, of the panel of 
transcription/co–repressor/co-activator factors forming complexes with the SMAD 
proteins determining which genes are targeted and in which direction, i.e. activating 
or inhibitory. Finally, the cell epigenetic status, regulating gene accessibility, 
influences the final response and determines which genes are available for the 




Figure 7. Contextual factors affecting TGF-β signaling and influencing the final transcriptional 
response. a. A first group of factors affecting the final response of a given cell to TGF-β includes 
ligands, receptors, co-receptors and ligand-traps (1). More downstream, inhibitory SMAD and the 
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type and intensity of the cross-talk between the SMAD and non-SMAD signaling pathways affect 
SMAD activity (2). On a transcriptional level SMAD form complexes with other transcription/co–
repressor/co-activator factors (3). Finally, the epigenetic status of the cells determines which genes 
are available for transcription (4). b. The three groups of context determinants affecting TGF-β 
signaling. EMT, epithelial–to-mesenchymal transition; HATs, histone acetyl transferases; HDAC, 
histone deacetylase; iPS cell, induced pluripotent stem cell; SWI/SNF, Switch/sucrose non 
fermentable (adapted from Massague 2012). 
 
 
3.3.4. TGF-β signaling in glioblastoma 
TGF-β signaling plays a central role in the malignant phenotype of glioblastoma by 
controlling several hallmarks of the disease promoting tumor cell proliferation, 
migration and invasion, exerting strong immunosuppressive activities, inducing 
angiogenesis, contributing to tumor chemo- and radio-therapy resistance, and by 
sustaining glioma stem cell stemness (Figure 8) (Joseph et al., 2013). Several 
studies demonstrated that glioma cells produce high levels of TGF-β (Wrann et al., 
1987; Constam et al., 1992; Sasaki et al., 1995). Moreover, glioma patients show 
elevated TGF-β2 serum levels, with TGF-β2 levels negatively correlating with 
patient outcome (Schneider et al., 2006; Bruna et al., 2007). However, recent data 
from our laboratory challenge this view (Frei et al., 2015). In addition to tumor cells, 
also the microenvironment, including microglia and tumor vessels, contributes to the 
release of TGF-β in gliomas (Constam et al., 1992; Wesolowska et al., 2008; 
Dieterich et al., 2012). 
Gliomas are highly invasive, and TGF-β promotes cell invasiveness by inducing the 
expression of matrix metalloproteinases (MMP) and by suppressing MMP inhibitor 
(TIMP) expression (Nakano et al., 1995; Wick et al., 2001). Further, TGF-β promotes 
angiogenesis by regulating the expression of pro-angiogenic factors such as 
VEGFA (Sanchez-Elsner et al., 2001) and basic fibroblast growth factor (bFGF) 
(Pepper et al., 1990). Glioblastoma shows high vascular density with abnormal 
vessels (Wen and Kesari, 2008) and TGF-β2 has been suggested, together with 
VEGFA, as one of the main mediators to induce abnormal vasculature in 
glioblastoma (Dieterich et al., 2012). The role played by TGF-β in glioma immune 
escape has been extensively documented. Interestingly, the TGF-β2 isoform was 
discovered as the soluble factor released by glioma cells responsible for their 
immunosuppressive properties and in particular for the inhibition of T helper and T 
cytotoxic cells functions (Wrann et al., 1987). The immunosuppressive effect of 
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TGF-β in glioma depends on its action on both the tumor and the immune cells. On 
the one hand TGF-β2 favors tumor cells immune escape by promoting the 
downregulation of human leukocyte antigen DR (HLA-DR) (Zuber et al., 1988) and 
natural killer group 2D (NKG2D) ligand expression (Eisele et al., 2006) in glioma 
cells. On the other hand TGF-β inhibits the proliferation and cytotoxic activity of T 
cells (Friese et al., 2004), induces regulatory T cells differentiation and inhibits 
microglia (Suzumura et al., 1993) and natural killer (NK) cells (Joseph et al., 2013). 
Indeed, the use of the ALK-5 inhibitor SD-208 in tumor-bearing mice led to an 
increase in the number of NK, T-cytotoxic lymphocytes and macrophages infiltrating 
the tumor (Uhl et al., 2004). The inhibition of TGF-β by the neutralizing monoclonal 
antibody 1D11 in glioma-bearing mice increased the response to tumor vaccination 
based on the use of glioma-associated peptides, by increasing the response and 
tumor-recruitment of glioma-associated antigens reactive T-cytotoxic lymphocytes 
and by reducing the number of Treg infiltrating the tumor (Ueda et al., 2009). 
TGF-β signaling has been associated with therapy resistance in gliomas and in 
particular with radiotherapy resistance. The irradiation of glioma cells led to 
increased TGF-β secretion and to enhanced invasiveness in one cell line (Canazza 
et al., 2011), suggesting that TGF-β may play a role in the tumor cell invasiveness 
observed at the site of irradiation in glioblastoma patients (Han et al., 2015). 
Treatment of glioma cells with the TGF-β receptor type I/II dual inhibitor LY2109761 
increased the cytotoxic effect of radiation treatment with enhanced DNA damage 
and apoptosis (Zhang et al., 2011).  
Different reports have revealed an important role for TGF-β in the maintenance of 
the stem cell-like properties and the tumorigenic activity of GIC (Ikushima et al., 
2009; Gargiulo et al., 2013) with GIC expressing high levels of TGF-β2 (Qiu et al., 
2011). In GIC TGF-β promotes the expression of the leukemia inhibitory factor (LIF) 
increasing GIC self-renewal and reducing cell differentiation (Penuelas et al., 2009). 
Also, TGF-β, by directly controlling SOX4 expression, promotes SOX2 expression, 
a known regulator of cell stemness (Ikushima et al., 2009). Notably, it has been 
reported that TGF-β inhibitors, when used in vivo, may target the GIC compartment 





Figure 8. TGF-β control of glioblastoma hallmarks. TGF-β controls the malignant phenotype of 
glioblastoma by promoting migration and invasion, by exerting strong immunosuppressive functions, 
by inducing angiogenesis, by sustaining stem cell stemness and by increasing tumor resistance to 
irradiation and chemotherapy (adapted from Joseph et al. 2013).  
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3.4. PROPROTEIN CONVERTASES 
 
3.4.1 The family of proprotein convertases 
Proprotein-convertases subtilisin/kexin (PCSK) form a family of calcium-dependent 
serine endoproteases related to bacterial subtiliases and yeast kexins. The PCSK 
family consists of seven core members, PCSK1, PCSK2, PCSK3 known as furin, 
PCSK4, PSCK5, PCSK6 also known as PACE4 and PCSK7 and two structurally 
unrelated members, PCSK9 and MTBPS1 (Figure 9) (Seidah and Prat, 2012). The 
seven PCSK core members are synthesized as pre-pro-proteins (Artenstein and 
Opal, 2011). The amino-terminal pro-domain regulates folding, activation, transport, 
and activity of PCSK (Anderson et al., 2002). The pro-domain is followed by the 
catalytic domain and by the P domain (Figure 9). The last one is conserved among 
the seven enzymes and regulates the enzymatic activity and its dependency on pH 
and calcium concentration. Depending on the specific PCSK, the carboxy-terminal 
region may contain transmembrane and cytosolic domains responsible for the 
controls of PCSK trafficking through the different subcellular compartments 
(Artenstein and Opal, 2011). The seven core members process their substrates at 
single or paired basic residues, (R/K)Xn(R/K) (Duckert et al., 2004). PCSK are 
involved in the processing of a wide range of substrates, including growth factors, 
growth factors receptors, hormones, adhesion molecules as well as molecules of 
viral, bacterial and parasitic origin (Artenstein and Opal, 2011). Protein processing 
by PCSK has mainly an activating effect, but it can also lead to protein inactivation. 
PCSK acts in different subcellular compartments, including the trans-Golgi network, 
cell surface and endosomes as well as the extracellular space (Seidah and Prat, 
2012).  
About cleaved substrates, some PCSK and mainly PCSK5, PCSK7, furin and 
PACE4 show redundancy in vitro. The selectivity in vivo is dependent on the spatial-
temporal co-localization of a specific substrate and a determinate PCSK. This co-
localization may be passive, like the concomitant presence of furin and TGF-β in the 
trans-Golgi network or can be active like the co-localization of furin and nodal 
promoted by the co-receptor crypto (Blanchet et al., 2008)  
The main properties of the seven PCSK members, which process their substrate at 
the consensus recognition sequence which is also present in TGF- precursor are 
described in the following. 
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- PCSK1 and PCSK2 are often co-expressed and usually act in a complementary 
way (Seidah and Prat, 2012). They are expressed in neural and endocrine cells 
where they localize in the secretory granules of the constitutive secretory pathway. 
The substrates processed by PCSK1 and PCSK2 include pro-hormones like pro-
insulin, thyrotropin-releasing hormone (TRH) and melanin-concentrating hormone 
(MCH) and neuropeptide precursors. PCSK1 knockout (Zhu et al., 2002) and 
PCSK2 knockout mice (Furuta et al., 1997) show severe metabolic and growth 
problems. PCSK1 knockout mice also show partial perinatal lethality, whereas 
PCSK2 knockout mice are viable. Human beings with PCSK1 loss are affected by 
diabetes, hypothyroidism, and hypogonadism (Creemers et al., 2012).  
 
- PCSK4 has been detected only in tissues of the reproductive system and in 
particular in the ovary, placenta, and testicular germ cells. It is involved in the 
cleavage of metalloproteases of the a disintegrin and metalloprotease (ADAM) 
family, pituitary-adenylate cyclase-activating polypeptide and insulin growth factor 
(IGF)2 (Seidah and Prat, 2012). PCSK4 knockout mice show impaired fertility 
(Mbikay et al., 1997). 
 
- Two different splice isoforms of PCSK5 have been described, PCSK5A and 
PCSK5B, which act at the cell surface or ECM. PCSK5A is secreted, whereas 
PCSK5B is a transmembrane protein which is shed and released extracellularly 
(Seidah and Prat, 2012). The expression pattern of PCSK5 is quite broad and 
includes the intestine, the kidney, the ovary and the adrenal cortex. The expression 
pattern of PCSK5 partially overlaps with the one of PACE4 with which it also shows 
in vitro and ex vivo enzymatic redundancy (Seidah and Prat, 2012). PCSK5 
specifically processes GDF11 and mice with PCSK5 loss die at birth showing 
malformations similar to GDF11 knockout mice (Essalmani et al., 2008). In addition 
to GDF11, PCSK5 is also known to process adhesion molecules like neuronal 
L1CAM and integrin alpha4 (Seidah and Prat, 2012). 
 
- PACE4 is mainly secreted and acts at the cell surface or in the extracellular matrix. 
It shows expression overlaps with PCSK5 and in vitro and ex vivo redundancy with 
furin and PCSK5 (Seidah and Prat, 2012). The substrates processed by PACE4 
include the metalloproteinase ADAM-TS4, the growth factors nodal and lefty and 
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also some viral glycoproteins (Seidah and Prat, 2012). Mice with PACE4 knockout 
die as embryos in the 25% of cases depending on the genetic background with 
cardiac malformations and defects in the right-left patterning (Constam and 
Robertson, 2000). 
 
- PCSK7 acts only intracellularly being expressed in the trans-Golgi network and in 
endosomes (Rousselet et al., 2011). PCSK7 show an ubiquitous expression pattern 
with some partial redundancy with furin, PCSK5 and PACE4 (Seidah and Prat, 
2012). PCSK7 processes transferrin receptor-1 being consequently involved in iron 
metabolism (Guillemot et al., 2013). Besides, it can process pro-BDNF (Wetsel et 
al., 2013) and some viral proteins and it is involved in the regulation of dopaminergic 
circuits in the central nervous system. In accordance, mice with a PCSK7 knockout, 
which are vital, show learning and memory deficits (Wetsel et al., 2013). 
 
- Furin localizes in the trans-Golgi network, at the cell surface, in recycling 
endosomes and, upon shedding, it can be released into the extracellular 
environment (Denault et al., 2002). Furin shows ubiquitous expression and 
substrate redundancy with PCSK5, PCSK7, and PACE4 (Thomas, 2002). Furin 
processes a high number of substrates including coagulation factors like factor IX 
and von Willebrand factor, growth factors including members of TGF-β superfamily 
such as TGF-β (Dubois et al., 2001), BMP4 (Cui et al., 1998) and nodal, IGF1 and 
its receptor (Khatib et al., 2001), beta-NGF (Molloy et al., 1999), VEGFC and D 
(Siegfried et al., 2003), PDGF (Siegfried et al., 2005), MMP, members of the tumor 
necrosis factor (TNF) family and integrins (Thomas, 2002). In addition to 
endogenous molecules, furin is involved in the processing and activation of 
pathogen associated molecules. Furin cleavage is required for the activation of 
some toxins, such as Shiga and Diphtheria toxins (Artenstein and Opal, 2011). 
Several viruses require furin processing of their envelope glycoproteins to properly 
fuse with the membrane of host cells, and these include human immunodeficiency 
virus type I, influenza A viruses, avian influenza viruses like the H5N1 strains, 
paramoxyvirus, cytomegalovirus and Ebola virus (Artenstein and Opal, 2011).  
Furin knockout mice die at the embryonic stage with several severe malformations 
(Roebroek et al., 1998).  
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3.4.2 PCSK in disease and their therapeutic targeting 
PCSK play fundamental roles in embryogenesis and development as well as in 
keeping tissue homesteosasis in the adult. The deregulation of their activity 
associate with different pathological states (Artenstein and Opal, 2011). This 
prompted the development of PCSK inhibitors with therapeutic purposes (Artenstein 
and Opal, 2011; Seidah and Prat, 2012). 
The lethal phenotype of knockout mice for furin, PACE4 and PCSK5, their 
ubiquitous expression as well as the redundancy in substrates may require cell- or 
tissue-specific targeting approaches (Artenstein and Opal, 2011; Seidah and Prat, 
2012).  
As mentioned above, alterations in PCSK1 and PCSK2 have been associated with 
endocrinopathies. A molecule blocking glucan processing by PCSK2 and promoting 
pro-insulin processing by PCSK1 for the potential treatment of diabetes has been 
suggested (Vivoli et al., 2012). The involvement of PCSK and mainly furin in viral 
infections led to the evaluation of the antiviral effect of PCSK inhibitors. For some of 
them, the efficacy in vitro as well as in vivo in animal models has been proven 
(Artenstein and Opal, 2011; Seidah and Prat, 2012). PCSK are often deregulated in 
cancer and metastasis (Artenstein and Opal, 2011; Seidah and Prat, 2012). Furin, 
PCSK5, PACE4 and PCSK7 are the most commonly up-regulated PSCK in cancers 
(Cheng et al., 1997; Bassi et al., 2000; Bassi et al., 2001; Mahloogi et al., 2002; 
Bassi et al., 2003; Bassi et al., 2010; D'Anjou et al., 2011). Increased levels of 
PCSK1 and PCSK2 have been reported in neuroendocrine tumors (Kajiwara et al., 
1999) and lung cancer, too (Creemers et al., 1992). In gliomas PACE4 has been 
identified as a glioma invasion-associated enzyme (Delic et al., 2012). Also, furin 
inhibition in astrocytoma cells suppressed their growth and invasiveness (Mercapide 
et al., 2002) and the use of a PCSK inhibitor revealed that pro-TGF-β is processed 
by cytoplasmic and secreted PCSK in gliomas (Leitlein et al., 2001). Several 
approaches have been suggested to inhibit furin in cancer, including small inhibitors 
and different studies revealed their efficacy in reducing cell growth and invasiveness 
(Mercapide et al., 2002; Scamuffa et al., 2008). None of these furin inhibitors 
entered clinical trials (Seidah and Prat, 2012). A phase I clinical trial based on 
DNA/autologous tumor cell vaccination and involving furin gene silencing brought 
promising results. In this study, patients with advanced cancers including 
melanoma, colon and ovarian cancers, were intradermally implanted with 
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autologous tumor cells that were previously transfected with a plasmid encoding for 
granulocyte-macrophage colony-stimulating factor (GM-CSF) and for two shRNA 
targeting furin. The decrease in TGF-β levels in tumor cells as a consequence of 
furin gene silencing, in combination with high expression of GM-CSF, induced an 
effective tumor response and led to prolonged survival (Senzer et al., 2012). 
 
 
Figure 9. The family of PCKS. The primary schematic structure, domain composition and 
glycosylated sites of PCSK are indicated. The consensus sequence of the seven PCSK core 
members is reported in the right lower corner. PCSK, proprotein convertases subtilisin/kexin; PC, 




3.5. FIBRONECTINS (FN) 
 
3.5.1 The FN isoforms containing the extra-domains A and B 
FN are high molecular mass adhesive glycoprotein of the extracellular matrix 
(Pankov and Yamada, 2002). They are present in the ECM of solid tissues as well 
as in body fluids. FN are modular proteins characterized by the repetition of three 
different domains, named FN type I, type II and type III domains. FN molecules form 
dimers by two disulfide bridges in the carboxy-terminal region (Figure 10). They are 
involved in the regulation of several cell functions including cell growth and 
differentiation, cell adhesion, cell migration, establishment and maintenance of 
normal cell morphology and hemostasis (Hynes, 1990). These functions are 
mediated by the interaction of FN with other components of the ECM, like collagen, 
heparin and chondroitin sulfate, with cellular integrins and with growth factors 
including VEGF and TGF-β. FN are encoded by a single gene on chromosome 2 
(Zardi et al., 1982), but up to twenty isoforms may be generated by post-translational 
modifications such as glycosylation as well as by alternative splicing mechanisms 
(Pankow Yamada 2002). Alternative splicing can affect three different domains: the 
extra domain A (EDA), the extra-domain B (EDB) and the type III connecting 
sequence (IIICS) (Schwarzbauer, 1991). Alternative splicing of FN is regulated by 
several factors including pH and cytokines and TGF-β has been identified as one of 
the most important regulators of this process, leading to an increase in EDA+FN 
and EDB+FN levels in several cell types (Balza et al., 1988; Borsi et al., 1990; Viedt 
et al., 1995). The inclusion of these domains in FN molecules leads to the 
introduction of additional integrin binding sites, but it also leads to conformational 
modifications with exposure of otherwise cryptic sequences finally affecting ECM 
matrix assembly and cell signaling (Carnemolla et al., 1992; Leahy et al., 1996; 
Bencharit et al., 2007). 
The FN isoforms containing the EDA and EDB domains are abundantly expressed 
in fetal tissues, and during development, by contrast, their expression is restricted 
in the adult (White et al., 2008). EDA+FN in the adult is expressed in neo-forming 
vessels, in inflamed and fibrotic tissues, in wounds and tumors. The EDA domain 
directly interacts with the integrins α9β1 (Shinde et al., 2008) and α4β1 (Shinde et 
al., 2015) and with toll-like receptor 4 (TLR4). The presence of EDA domain in FN 
molecules also increases binding to the integrin α5β1 (Manabe et al., 1997). By 
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interacting with the integrins mentioned above, EDA+FN modulates adhesion of the 
cell to the ECM (Shinde et al., 2008; Shinde et al., 2015). By controlling the 
activation of TGF-β and by promoting α-smooth muscle cell actin (α-SMA) 
expression EDA+FN mediates activation and differentiation of fibroblasts into 
myofibroblasts and thus plays an important role in wound healing (Muro et al., 2003) 
and fibrogenesis (Serini et al., 1998; Muro et al., 2008; White et al., 2008; Kohan et 
al., 2010; Kawelke et al., 2011). The interaction of EDA+FN with TLR4 has been 
associated with immune and pro-inflammatory functions, such as the enhancement 
of cytotoxic responses (Julier et al., 2016) and the activation of macrophages 
(Doddapattar et al., 2015). In addition, EDA+FN is involved in morphogenesis of 
lymphatic vessels (Bazigou et al., 2009) and in sustaining the stemness properties 
of embryonic stem cells (Losino et al., 2013), of colorectal cancer stem cells (Ou et 
al., 2013) and in promoting colorectal cancer metastasis. Importantly, this may be 
due to its role in inducing epithelial-to-mesenchymal transition (Ou et al., 2014). The 
high expression of EDA+FN in chronically inflamed tissues has prompted the 
development of recombinant antibodies specific for EDA fused with the cytokines 
IL-4 and IL-10. These molecules, allowing targeting (via EDA) and treatment (via IL-
4 or IL-10) of in vivo chronic inflamed tissues, are currently tested in clinical trials in 
patients with rheumatoid arthritis and endometriosis (Galeazzi et al., 2014). 
The FN isoform containing the EDB domain is expressed in the adult in tissues 
undergoing remodeling and angiogenesis, being abundantly expressed in 
neoplastic tissues (Zardi et al., 1987; Kaczmarek et al., 1994; Kosmehl et al., 1996). 
During angiogenesis, EDB+FN accumulates around newly formed vessels, and it is 
thus considered a marker of this process (Castellani et al., 1994). Glioblastoma 
vessels show abundant expression of EDB+FN. Also, it has been shown that in 
gliomas the percentage of vessels positive for EDB+FN correlates with tumor grade 
(Castellani et al., 2002). The biological functions of EDB as well as its potential 
binding partners are not yet clear. Recently, a role for EDB in the regulation of VEGF 
expression in endothelial cells has been suggested (Khan et al., 2005; Chen et al., 
2012) as well as a role in promoting phagocytosis in an αvβ3-dependent manner 
(Kraft et al., 2016). The high expression of EDB+FN in tumors and tumor vasculature 
has prompted the development of EDB+FN-specific antibodies for diagnostic and 
therapeutic purposes. In particular the EDB-specific recombinant antibody L19 (Pini 
et al., 1998) is currently under investigation in clinical trials in cancer patients as 
45 
 
fusion protein with the cytokines IL-2 (Carnemolla et al., 2002; Zegers et al., 2015) 
and TNF-α (Borsi et al., 2003; Danielli et al., 2015) as well as radio-labeled molecule 




Figure 10. The modular structure of fibronectin. Fibronectin (FN) is a modular protein 
characterized by the repetition of three different types of domains, known as FN type I, II and III 
repeats. Alternative splicing can affect three different regions: the extra-domain A (indicated in 
green), the extra-domain B (ED-B) (indicated in red) and the type III connecting sequence (IIICS) 




3.5.2 FN in vascular morphogenesis and plasticity 
Fibronectins evolutionary appeared with the appearance of an endothelium–lined 
vasculature (Hynes and Zhao, 2000). Genetic studies performed in mice, zebrafish 
and xenopus attested a role for fibronectin in vascular morphogenesis and 
cardiovascular development (Astrof and Hynes, 2009). Indeed FN-null embryos die 
because of lethal vascular defects at embryonic (e) day 8-8.5 (George et al., 1993; 
George et al., 1997; Francis et al., 2002). Several functions of FN in vascular 
morphogenesis are dependent on the interaction of FN with integrins and mainly 
with the integrin α5β1. FN-α5β1 binding is mediated by the RGD sequence located 
on the FN type III domain 10 and by a synergy site belonging to the FN type III 
domain 9 (Leahy et al., 1996). Embryos of knockout mice for integrin α5 and of 
transgenic mice in which the RGD sequence was substituted by a RGE sequence 
died at days e9.5-10 and e10, respectively, and showed severe vascular defects, 
even if slightly milder, to the ones reported for FN knockout mice (Yang and Hynes, 
1996; Takahashi et al., 2007). These studies attest a central role for FN and α5β1 
in vascular morphogenesis. The higher severity of the phenotype of FN knockout 
mice suggests that other FN functions independent of the interaction with α5β1 are 
involved. The specific role of the EDA and EDB splice variants of FN in vascular 
morphogenesis is less clear. EDA/EDB double knockout mice embryos die between 
days e9.5 and e10.5 from severe cardiovascular defects (Astrof et al., 2007). By 
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contrast, single EDA and EDB knockout mice are viable and fertile (Fukuda et al., 
2002; Muro et al., 2003). EDA/EDB double null mice embryos show sheets of 
endothelial cells instead of vascular networks (Astrof et al., 2007). Interestingly, the 
phenotype of these double null mice is similar to the ones reported for mice carrying 
deletions in different molecules involved in vascular morphogenesis and plasticity, 
i.e. VEGF-A, angiopoietin (Ang)1, bFGF and TGF-β1 (Dickson et al., 1995; Ferrara 
et al., 1996; Lee et al., 2000). Several hypotheses exist for the potential mechanisms 
responsible for the phenotype of EDA/EDB double knockout mice and its similarity 
with knockout mice of the above-mentioned growth factors including a potential role 
of the EDA and EDB domains in regulating growth factor signaling (Astrof and 
Hynes, 2009). FN-α5β1 interactions are involved in the signaling of various growth 
factors including PDGF-BB, EGF, bFGF and TGF-β1 (Astrof and Hynes, 2009). 
Beyond, FN mediates TGF-β1 signaling through SMAD1,5,8 by promoting the 
formation of an ALK-1/endoglin complex in human microvascular endothelial cells 
(Tian et al., 2012). A potential role for the EDA and EDB domains in modulating 
TGF-β signaling has been hypothesized (Astrof and Hynes, 2009). 
 
Endothelial cells show high phenotypic plasticity which is a consequence of their 
exposure to a high variety of stimuli, represented by both soluble factors, such as 
cytokines and growth factors and mechanical forces (Dejana et al., 2017). The 
hallmark of endothelial cell plasticity is endothelial-to-mesenchymal transition 
(EndMT). The process of EndMT is characterized by the progressive loss of 
endothelial properties and gain in mesenchymal properties (Goumans et al., 2008). 
Endothelial cells undergoing EndMT show cytoskeleton rearrangements, loss of cell 
polarity and alteration in endothelial junctions, paralleled by the acquisition of a 
fibroblast morphology, increased FN and collagen secretion and an increase in 
motility, proliferative, migratory, invasive and thrombogenic abilities (Kalluri and 
Weinberg, 2009). Endothelial cells undergoing EndMT acquire properties of 
different mesenchymal-lineage cell types such as fibroblasts, smooth muscle cells, 
chondrocytes or adipocytes (Dejana et al., 2017). During EndMT endothelial cells 
start to express mesenchymal markers such as α-SMA and neural (N)-cadherin and 
progressively loose the expression of endothelial markers such as CD31 and 
vascular endothelial (VE)-cadherin (van Meeteren and ten Dijke, 2012).  
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EndMT occurs during development, where it plays a fundamental role in cardiac 
development (Thiery and Sleeman, 2006) generating cardiac fibroblasts and 
smooth muscle cells, as well as in postnatal settings. Postnatal EndMT is associated 
with different pathological conditions including tissue fibrosis (Piera-Velazquez et 
al., 2011), atherosclerosis (Chen et al., 2015) and cancer (Zeisberg et al., 2007; 
Xiao et al., 2015). In cancer, EndMT contributes to the generation of cancer-
associated fibroblasts and thus favors tumor progression and invasion. Also, by 
reducing endothelial cell junctions, it facilitates tumor cells intravasation and 
metastatic dissemination (Dejana et al., 2017).  
Several signaling pathways promote EndMT with TGF-β signaling playing a central 
role in the regulation of plasticity of endothelial cells. In endothelial cells, TGF-β can 
activate both the ALK-5/SMAD2,3 and ALK-1/SMAD1,5,8 signaling pathways, with 
the ALK-5/SMAD2,3 pathway promoting endothelial cells quiescence and the ALK–
1/SMAD1,5,8 pathway stimulating proliferation and migration of endothelial cells. It 
has been proposed that the balance between these two signaling pathways as well 
as their cross-talk affects the activation state of endothelial cells (Goumans et al., 
2002). Different studies show that TGF-β may induce the process of EndMT in 
endothelial cells, with a preferential involvement of SMAD3-dependent signaling 
(van Meeteren and ten Dijke, 2012). TGF-β induces the expression of transcription 
factors such as Snail, Slug and Twist that in turn regulate the expression of several 
genes involved in the process of EndMT (Medici et al., 2011). Also, TGF-β can 
directly induce the expression of proteins which are considered as markers of 
EndMT (Dejana et al., 2017), including FN. Recently, it has been shown that TGF-
β induces EndMT in endothelial cells derived from freshly dissociated human 
glioblastoma in an ALK-5-dependent manner (Krishnan et al., 2015). 
Glioblastomas are characterized by a high vascular density, vascular 
abnormalization and the formation of glomeruloid vascular structures (Wen and 
Kesari, 2008). Among the genes up-regulated in glioblastoma tumor vasculature are 
several EndMT markers including fibronectin. Beyond, SMAD3/SMAD4 complexes 
are preferentially localized in the vasculature or the perivascular areas, suggesting 
a direct contribution of TGF-β signaling in the expression of genes responsible for 
glioblastoma vasculature abnormalization (Dieterich et al., 2012). Recently, it has 
been demonstrated that glioblastoma-derived endothelial cells, undergoing EndMT, 
acquire a fibroblast-like phenotype, express high amount of ECM proteins including 
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FN, become more invasive and contribute to glioblastoma vessels abnormalization 
(Huang et al., 2016).   
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4. MATERIAL AND METHODS 
 
Cell culture and reagents 
LN-229 and LN-308 kindly provided by N. de Tribolet (Lausanne, Switzerland) were 
cultured in DMEM (Gibco/Thermo Fisher, Madison, WI) supplemented with 1% L-
glutamine (Gibco) and 10% FBS (Gibco). The human GIC T-325, T-269, ZH-161, 
S-24 and ZH-305 (Lemke et al., 2014) were cultured in phenol red-free neurobasal 
medium (NBM) (Gibco) supplemented with 2% B-27 without vitamin A (Gibco) (20 
μl/ml), 1% L-glutamine (Gibco) and fibroblast growth factor and epidermal growth 
factor (FGF/EGF) (20 ng/ml each) (PeproTech, London, UK). Treatment of cells was 
performed in NBM containing 1% L-glutamine and FGF/EGF. 
Lentivirally-mediated gene silencing of furin was performed as described (Szabo et 
al., 2016) using a furin specific shRNA (V3LHS_310002) cloned in a pGIPZ lentiviral 
vector and the respective pGIPZ vector carrying a non-targeting control (RHS4349) 
(Dharmacon, Lafayette, CO). 
Transient gene silencing was performed by electroporation (Neon Transfection 
System, Invitrogen/ Thermo Fisher) using 100 nM of the following ON-TARGET 
plus, siRNA SMART pools from Dharmacon: TGF-β1 (L-012562-00), SMAD2 (L-
003561-00), SMAD3 (L-020067-00), SMAD4 (L-003902-00), ERK1 (L-003592-00), 
ERK2 (L-003555-00) and non-targeting control (D-001810-10). 
Human cerebral microvascular endothelial cells (hCMEC/D3) were kindly provided 
by P.C. Couraud (Paris, France). The human glioblastoma-derived endothelial cells 
ZHE-464, ZH-483-2 and ZHE-459 were previously reported (Krishnan et al., 2015). 
Endothelial cells were cultured in EBM-2 medium (CC-3156, Lonza, Walkersville, 
MD), containing 0.1 M HEPES (Gibco), 1% v/v CD lipid concentrate (Gibco) and 
endothelial growth supplements (EGM-2-CC4176, Lonza).  
Transient gene silencing in endothelial cells was performed by using the 
Lipofectamine RNAiMAX reagent (Invitrogen) and the above described siRNA 
specific for SMAD2,3,4 and siRNA control. For EDA+FN and EDB+FN the following 
siRNA provided by Dharmacon and used at the final concentration of 10 nM were 
used: 1) EDA+FN: pool of siEDA1 5'- GGTTCTGAGTACACAGTCA-3' and siEDA2 
5'- GGTTCTGAGTACACAGTCA - 3'; 2) EDB+FN: pool of four siRNA previously 
described (Khan et al., 2005). 
Cells were treated in EBM-2 medium without supplements. 
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Human peripheral blood mononuclear cells (PBMC) were prepared from healthy 
donor blood and cultured in RPMI (Gibco) supplemented with 10% fetal bovine 
serum (FBS) (Gibco), 20 mM L-glutamine, 50 µM β-mercaptoethanol (Sigma, St. 
Louis, MO), 10 U/ml penicillin (Sigma), 10 µg/ml streptomycin (Sigma), 10 mM 
sodium-pyruvate (Sigma), and 1x Minimum essential medium nonessential 
aminoacids (Gibco). Media from GIC seeded at 107 in 10 ml NBM for 72 h were 
concentrated 2.5-fold prior to the addition to the PBMC. On day 0 PBMC were 
treated with 3 µg/ml concavalin A (Sigma), 20 U/ml IL-2 (PeproTech) and GIC 
conditioned media. At day 3 treatment with IL-2 and exposure to GIC media were 
repeated, and at day 6 addition of IL-2 was repeated. On day 7 cells were analyzed 
by flow cytometry. 
The following reagents were used: PCSK inhibitor Decanoyl-RVKR-CMK (3501, 
Tocris Bioscience, Bristol, UK), recombinant human TGF-β2 (R&D Systems, 
Minneapolis, MN), SD-208 (Scios, Fremont, CA), mitogen-activated 
protein/extracellular signal-regulated kinase (MEK)1/2 inhibitor U0126 (9903, Cell 
Signaling Technology, Danvers, MA), JNK inhibitor SP600125 (Sigma-Aldrich). The 
human fibronectin recombinant fragments used in this study were previously 
described (Carnemolla et al., 1996). 
 
Immunoblot analysis 
Whole cell lysates or concentrated conditioned media in denaturing and reducing 
conditions were separated by using 10% or 12% polyacrylamide gels and 
transferred to nitrocellulose membranes (Amersham/Ge Healthcare Life Science, 
Arlington Heights, IL). After staining with red ponceau (ApplChem, Darmstadt, 
Germany) for equal loading, membranes were blocked with 5% skimmed milk or 
serum bovine albumin (ApplChem) and treated with primary antibodies. Protein 
bands were visualized with horseradish peroxidase (HRP)-coupled secondary 
antibodies followed by enhanced chemoluminescence (Pierce/Thermo Fisher, 
Madison, WI). Primary antibodies used were anti-furin (sc-20801, Santa Cruz 
Biotechnology, Dallas, TX), anti-β-actin (sc-1616, Santa Cruz), anti-human 
LAP/TGF-β1 (AF-246-NA, R&D Systems), anti-TGF-β1 (G1221, Promega, 
Madison, WI), anti-TGF-β2 (ab36495, Abcam, Cambridge, UK), anti-GAPDH 
(EB07069, Everest Biotech, Ramona, CA) and antibodies from Cell Signaling 
Technology specific for SMAD1 (9743), phosphorylated SMAD1/5 (Ser463/465) 
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(9516), SMAD2 (3122), phosphorylated SMAD2 (Ser465/467) (3108), SMAD3 
(9513), phosphorylated SMAD3 (Ser423/425) (9520), SMAD4 (9515), p44/42 
MAPK (ERK1/2) (9102), phosphorylated p44/42 MAPK (ERK1/2) (Thr202/Tyr204) 
(9106), AKT (9272), phosphorylated AKT (Ser473) (9271), p38 MAPK (9212), 
phosphorylated p38 MAPK (Thr180/Tyr182) (9211). FN, EDA+FN and EDB+FN 
were detected by using the IST4 (Sekiguchi et al., 1985), IST9 (Borsi et al., 1987) 
and C6 (Balza et al., 2009) antibodies, respectively. Secondary antibodies were 
HRP-coupled goat anti-rabbit (sc-2004), donkey anti-goat (sc-2033) (Santa Cruz 
Biotechnology) or sheep anti-mouse antibodies (NA931V, Ge Healthcare UK 
limited, Amersham, UK). 
 
Real-time polymerase chain reaction (RT-PCR) 
RT-PCR was performed by using the ΔCTT- method with ARF1 as a housekeeping 
gene. The following primers were used: PCSK1 for 5’-
CCTGGAAGCAAACCCAAATC-3’, PCSK1 rev 5’-
CAGACAACCAGGTGCTGCATA-3’, PCSK2 for 5’-
AATGCCGAAGCAAGTTACGACT-3‘, PCSK2  rev 5’-
CCCGTGGCTGTTAAACCAGT-3’, PCSK4 for 5’-AGCAAAGAGAACCGGCACG-3’, 
PCSK4 rev 5’-TCGATGACATCGGTGATGGT-3’, PCSK5 for 5’-
GGCCAACAGGCTATTTGATCA-3', PCSK5 rev 5’-GCTCTTTCTCCCCAGCAATG-
3', PCSK6 for 5’-CACCTGCTAGTGAAGACATCC-3', PCSK6 rev 5’-
AACGAGAGCTTCTGCGTCCAC-3', PCSK7 for 5’-CCACCCGGTATGAGGATCG-
3’, PCSK7 rev 5’-AAACCGTGCTGGTGGCTATG-3’, furin for 5’-
GGACTAAACGGGACGTGTACC-3’, furin rev 5'-AGGCCGCCTTCACATTCAG-3’, 
FN for 5'-TACACTGGGAACACTTACCG-3', FN rev 5'-
CCAATCTTGTAGGACTGACC-3’, EDA+FN for 5'-
GGAGAGAGTCAGCCTCTGGTTCAG-3', EDA+FN rev 5’-
TCTGCAGTGTCTTCTTCACC-3’, EDB+FN for 5'-
TCAAGGATGACAAGGAAAGTG-3', EDB+FN rev 5'-
AATAATGGTGGAAGAGTTTAGC-3', ID1 for 5'-CCAGCACGTCATCGACTACA-3', 
ID1 rev 5’-GGAACGCATGCCGCC-3’, PAI-1 for 5'-
CAGAAAGTGAAGATCGAGGTGAAC-3', PAI-1 rev 5’-
GGAAGGGTCTGTCCATGATGAA-3’, ARF1 for 5'-GACCACGATCCTCTACAAGC-




Cellular and extracellular furin-specific activity (FSA) was measured as previously 
described (Bourne and Grainger, 2011) using the anti-furin antibody MAB15032 
(R&D Systems) as capturing antibody in lysates and conditioned media of cells 
seeded at a density of 5x106 cells in 7 ml NBM supplemented with L-glutamine and 
FGF/EGF for 48h. FSA is expressed as the fluorescence intensity (λexc=380nm, 
λem=460nm) normalized to protein concentration as determined by Bradford assay 
(Bio-Rad, Hercules, CA). FSA was measured in concentrated conditioned media 
mixed with the appropriate amount of reaction buffer and analyzed in the same 
manner as previously described for the lysates (Bourne and Grainger, 2011). 
 
Flow cytometry 
APC-CD25 (17-0259) and PE-FOXP3 (12-4776) antibodies were from eBioscience 
(San Diego, CA), FITC-CD4 (55346) from BD Biosciences (San Jose, CA). FOXP3 
Afixation/permeabilization kit (eBioscience) was used for FOXP3 staining. Cells 
were analyzed with FACS Verse (BD biosciences) and data analyzed with FlowJo 
software. Fluorescence Minus One (FMO) controls were performed by using the 
following fluorochrome-conjugated isotype control antibodies from BD biosciences: 
FITC-mouse IgG1, κ (555748), APC-mouse IgG1, κ (555751) and PE-rat IgG2A, κ 
(553930). 
 
Enzyme-linked immunosorbent assay (ELISA) 
BRAND Immunograde 96 wells plates (Sigma-Aldrich) were coated with 20 µg/ml 
gelatin in PBS overnight at room temperature, washed with PBS and blocked with 
2% BSA in PBS. Conditioned cell culture media were tested at different dilutions in 
2% BSA in PBS. FN, EDA+FN and EDB+FN were detected by using the IST4, IST9 
and C6 antibodies, respectively, diluted in 2% BSA in PBS. The minimal cross-
reactivity anti-mouse IgG-HRP antibody (BioLegend, San Diego, CA) was used as 
secondary antibody. 3,3’, 5,5’ tetramethylbenzidine (TMB) (BD Bioscience) was 
used as reaction substrate. Data are expressed as the values of absorbance at 450 





For immunohistochemical analysis 5 µm cryostat sections of ten human 
glioblastoma samples were used. Sections were stained using the primary 
antibodies IST-4, IST-9 and C6, the peroxidase mouse IgG Vectastain ABC kit (PK-
4002, Vector Laboratories, Burlingame, CA) and the DAB substrate (Peroxidase 
blocking, Dako-Agilent, Santa Clara, CA). 
 
Statistical analysis 
All experiments were performed at least twice and in triplicates. Statistical analysis 
was performed by using the GraphPad Prism 5 program. Data are shown as the 
mean ± the standard deviation (SD). The statistical significance of the data was 
determined by performing unpaired Student t-test or one-way Anova followed by 








Given the central role played by TGF-β in the malignant phenotype of glioblastoma 
and in GIC, the first goal of the project was to define the relevant PCSK for pro-TGF-
β processing with a particular focus on GIC. As furin was one of the main PCSK 
expressed in GIC, the aims of the project were: 
 
 To define the role played by furin in pro-TGF-β processing and TGF-β 
signaling performing a stable selective gene silencing of furin in GIC; 
 
 To investigate the regulation of furin levels with emphasis on TGF-β-





Since TGF-β and EDA+FN and EDB+FN are highly expressed in glioblastoma 
vasculature, the main goal of the project was to define the potential bi-directional 
interaction of TGF-β and FN in glioblastoma, focusing on endothelial cells. More 
specifically the aims of the project were: 
 
 To investigate the potential regulation EDA+FN and EDB+FN expression by 
TGF-β;  
 





6. RESULTS AND DISCUSSION 
 
6.1 Extracellular signal-regulated kinase 1 (ERK1) mediates the autocrine 
positive feedback loop of TGF-β and furin in glioma-initiating cells 
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Seven of the nine PCSK, i.e. PCSK1, PCSK2, PCSK4, PCSK5, PCSK6, PCSK7 
and furin, process their substrate at the consensus recognition sequence 
(R/K)Xn(R/K)↓ which is also the recognition site for processing TGF-β. We first 
investigated mRNA expression levels of these enzymes in a panel of five human 
GIC: T-325, T-269, ZH-161, S-24 and ZH-305. Furin was expressed in all cell lines 
and one of the most abundant PCSK (Figure 11A). Furin was detectable 
intracellularly in cell lysates as a double band of around 100 kDa, corresponding to 
the two glycosylated/sialylated forms of mature furin (Denault et al., 2002) except 
for T-269 where only the higher molecular mass isoform was detected. In the 
conditioned media furin was detectable as a major band with an apparent 
molecular mass of around 90 kDa (Figure 11B). 
 
Figure 11. Expression of proprotein convertases subtilisin/kexin (PCSK) in GIC. A. RT-PCR 
analysis of PCSK1, PCSK2, PCSK4, PCSK5, PCSK6, PCSK7 and furin. B. Analysis of furin levels 
by immunoblot in the lysates and conditioned media. 
 
To investigate the processing of TGF-β1/2 by furin, lentiviral gene silencing of furin 
was performed in T-325, ZH-161 and ZH-305 cells, further referred to as shfurin 
cells (Figure 12). Furin gene silencing did not affect any other PCSK with the 
exception of PCSK6 in ZH-305 shfurin cells (data not shown). Decreased protein 
levels of both cellular and secreted furin (Figure 12) and a reduction in cellular and 
extracellular furin-specific activity (FSA) (Figure 13) were confirmed in all furin 
knockdown cell lines. We then analyzed TGF-β1/2 processing in shfurin cells. For 
TGF-β1 we used an antibody to the N-terminus of TGF-β1 detecting both pro-TGF-
β1 (55kDa) and the latency associated peptide (LAP) of TGF-β1 (37 kDa) and an 
antibody to the C-terminus detecting mature TGF-β1 (12.5 kDa) (see ZH-
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161/siTGF-β1 as a control, Figure 12). For TGF-β2 we used an antibody reacting 
with the C-terminus of TGF-β2 detecting both pro-TGF-β2 (55 kDa) and mature 
TGF-β2 (12.5 kDa). Furin gene silencing resulted in increased levels of pro-TGF-β1 
and correspondingly decreased levels of the two respective processing products 
LAP/TGF-β1 and mature TGF-β1 in ZH-161 and ZH-305, with TGF-β1 being not 
detectable in T-325 (Figure 12). In T-325 and ZH-305, showing detectable TGF-β2 
protein levels, furin gene silencing increased levels of pro-TGF-β2 and decreased 
levels of mature TGF-β2. The effects of furin gene silencing on pro-TGF-β1/2 
processing were similar to those obtained with the pan-proprotein convertase 
inhibitor decanoyl-RVKR-CMK (PCSK inhibitor), suggesting that furin is the main 
PCSK involved in pro-TGF-β1/2 processing here. Notably, in T-325 and ZH-161 pro-
TGF-β processing takes place to a remarkable extent extracellularly as pro-TGF-β 
levels increased in shfurin cells and upon addition of the PCSK inhibitor in the 
conditioned media, but remained unchanged in the lysates. In ZH-305, the levels of 
pro-TGF-β2 increased both in cell lysates and in conditioned media following furin 
gene silencing, suggesting that pro-TGF-β2 processing takes place in part in the 
intracellular compartment in ZH-305 cells, too (Figure 12).  
 
Figure 12. Furin processes TGF-β in GIC. Protein levels of furin and precursor forms of TGF-β1/2 
were determined in cell lysates (upper panels) and conditioned media (lower panels) of furin-silenced 
or control cells or cells treated with 25 μM PCSK inhibitor Decanoyl-RVKR-CMK for 48h. Precursor 
and mature forms of TGF-β1/2 were determined in the conditioned media of control, furin-depleted 




Figure 13. Furin-specific activity (FSA) in GIC with furin gene silencing. Cellular and 
extracellular FSA was measured in lysates and conditioned media of control or furin-depleted cells. 
 
To confirm that reduced TGF-β levels affect down-stream signaling activities, we 
analyzed the levels of phosphorylated SMAD (pSMAD)2, pSMAD3 and pSMAD1,5 
as readouts for the activation of canonical TGF-β signal transduction, and of 
phosphorylated AKT (Ser473) (pAKT (Ser473)), ERK1/2 (pERK1/2) and p38 (pp38) 
reflecting non-canonical TGF-β signaling (Figure 14). All sh-furin cells showed 
reduced levels of pSMAD2 and pSMAD3. In ZH-161 and ZH-305 pSMAD1,5 was 
also reduced. The phosphorylation of AKT (Ser467) and p38 was reduced in T-325 
shfurin cells, and ZH-305 shfurin cells showed a reduction in the phosphorylation of 




Figure 14. TGF-β signaling in GIC with furin gene silencing. Total SMAD1,2,3, phosphorylated 
SMAD1,2,3,5, total and phosphorylated AKT, ERK1/2 and p38 levels were determined in control or 
furin-depleted cell lysates by immunoblot. In brackets the predicted molecular mass is indicated. 
 
TGF-β exerts several immunosuppressive functions, including the promotion of 
FOXP3+ Treg cells. Previous studies have demonstrated that GIC induce Treg 
generation in vitro (Wei et al., 2010). Accordingly, we treated human PBMC with 
GIC-conditioned media and confirmed the induction of CD4+CD25+FOXP3+ cells: 
conditioned media of ZH-161 cells increased the fraction of CD4+CD25+FOXP3+ 
cells from 8.9 to 14.8 ± 0.1%. TGF-β2 treatment was used as a positive control. To 
test whether the inhibition of TGF-β processing affected the ability of GIC to induce 
Treg, we exposed PBMC to media derived from GIC treated with the PCSK inhibitor. 
This led to a decrease in the induction of the CD4+CD25+FOXP3+ population from 
8.9 to 11.1 ± 0.5 % (Figure 15), indicating that the inhibition of TGF-β processing in 
GIC may reduce their immunosuppressive properties. Similar results were obtained 





Figure 15. The inhibition of TGF-β processing in GIC reduces the immunosuppressive 
properties of GIC. Human PBMC were treated with 2 ng/ml TGF-β2 or conditioned media from 
untreated ZH-161 cells or ZH-161 cells treated with 25 µM PCSK inhibitor Decanoyl-RVKR-CMK, in 
the presence of IL-2, for 7 days. Cells were stained for CD4 (FITC), CD25 (APC) and FOXP3 (PE). 
Scatter plots are gated on CD4+. P=0.0185 for media of ZH-161 treated with PCSK-versus untreated 
ZH-161, unpaired Student’s t-test. 
 
Autocrine production of TGF-β may be necessary to maintain GIC stemness and 
TGF-β signaling in the tumor microenvironment (Pickup et al., 2013), however, the 
mechanisms how GIC maintain high TGF-β activity is not well understood (Rodon 
et al., 2014). We therefore evaluated the effect of TGF-β2 on furin levels. Indeed, 
TGF-β2 induced the expression of furin and FSA in all cell lines except T-269 (Figure 
16A-C). To investigate whether the expression of PCSK other than furin was 
affected by TGF-β2, we analyzed the mRNA levels of the other six PCSK in ZH-161 
(Figure 16D), T-325 and ZH-305 cells (data not shown) treated with TGF-β2. Indeed, 
none of them was changed, pointing towards a specific effect of TGF-β2 on furin 
expression. Concentration and time dependency of furin induction was investigated 
in ZH-161 cells (Figure 16E-G). Since we observed an induction on protein levels 
after 24 h (Figure 16F) and the maximum effect was achieved with 2.5 ng/ml TGF-





Figure 16. TGF-β2 induces furin in GIC. A-B. Furin expression was analyzed on mRNA level by 
RT-PCR (A) and on protein level in cell lysates by immunoblot (B) in GIC treated with 2.5 ng/ml TGF-
β2 for 8 h (A) or 24 h (B). C. Furin-specific activity (FSA) was measured in the cell lysates and in 
conditioned media of T-325 and ZH-161 treated with 2.5 ng/ml TGF-β2 for 48 h. D. PCSK1, PCSK2, 
PCSK4, PCSK5, PCSK6, PCSK7 and furin mRNA levels in ZH-161 treated with 2.5 ng/ml TGF-β2 
for 24 h. E. Furin mRNA levels were measured by RT-PCR in ZH-161 treated with TGF-β2 for the 
indicated time points. F. Furin protein levels were analyzed in cell lysates and conditioned media of 
ZH-161 treated with 2.5 ng/ml TGF-β2 for the indicated time points by immunoblot. G. ZH-161 were 
treated with the indicated concentrations of TGF-β2 for 24 h. Furin protein levels were analyzed in 
cell lysates by immunoblot. 
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We proceeded to study the signal transduction mechanisms involved in the 
regulation of furin by TGF-β2. Exposure of T-325, ZH-161 and ZH-305 to the ALK-
5-specific inhibitor SD-208 had no effect on constitutive furin protein levels, but 
abolished TGF-β2-mediated furin induction (Figure 17). The transient gene silencing 
of SMAD2, SMAD3 or SMAD4 did not abrogate the induction of furin expression by 




Figure 17. TGF-β2 induces furin in GIC in an ALK-5-dependent manner. Furin levels were 
analyzed in the lysates of T-325, ZH-161 and ZH-305 treated with 2.5 ng/ml TGF-β2, 1 μM SD-208 





Figure 18. Furin induction by TGF-β2 in GIC is SMAD-independent. T-325, ZH-161 or ZH-305 
were transfected with siRNA targeting SMAD2 (upper panel), SMAD3 (central panel), SMAD4 (lower 
panel) or non-targeting control and 24 h later treated with 2.5 ng/ml TGF-β2 for 24 h. Furin was 
analyzed in the cell lysates by immunoblot. 
 
Indeed, blocking the MEK1/2 branch of the non-canonical TGF-β pathway by U0126 
decreased constitutive furin levels and attenuated the increase in furin levels in 
response to TGF-β2. U0126 also decreased constitutive furin levels in T-269 cells 
which are the TGF-β2/furin-non-responsive model (Figure 19A). The inhibitory effect 
of U0126 on the induction of furin expression by TGF-β2 translated into a reduction 
in FSA (Figure 19B). Similarly, the selective gene silencing of ERK1, but not of 
ERK2, reduced furin basal levels in all cell lines and attenuated the induction of furin 
by TGF-β2 (Figure 20). Gene silencing of ERK1, but not of ERK2, reduced furin on 




Figure 19. Furin induction by TGF-β2 requires the MEK1/2 pathway. A. Furin levels were 
determined in GIC pre-incubated with the MEK1/2 inhibitor U0126 (10 μM) for 1 h and then treated 
with 2.5 ng/ml TGF-β2 for 24 h. DMSO was used as solvent control. B. Furin-specific activity (FSA) 
was measured in the cell lysates and conditioned media of T-325 and ZH-161 cells pre-incubated 
with the MEK1/2 inhibitor U0126 (10 µM) or the respective DMSO control for 1 h and then treated 





Figure 20. ERK1 controls basal and TGF-β2-induced furin levels. Cells were transfected with 
siRNA pools targeting ERK1, the combination of ERK1 and ERK2 or non-targeting control. 48 h later 
T-325, ZH-161, S-24 and ZH-305 were treated with TGF-β2 for 24 h. Furin was analyzed in the cell 





Figure 21. ERK1 controls furin mRNA levels. Furin mRNA levels were determined by RT-PCR in 
ZH-161 cells transfected with siRNA targeting ERK1, ERK2, the combination of ERK1 and ERK2 or 
non-targeting control siRNA and 24 h later treated with TGF-β2 for 24h. Data are the mean of 
triplicates ± SD. 
 
To address whether the control of furin by ERK1 and TGF-β2 is associated with a 
glioma stem cell-like phenotype, we examined the same GIC cultured in 
differentiating conditions (Figure 22A) and the long-term glioma cell lines, LN-308 
and LN-229 (Figure 22B). In both cases ERK1 gene silencing reduced basal furin 
levels and attenuated the induction of furin by TGF-β2, suggesting that this 
molecular pattern is shared between cells with stemness properties and more 
differentiated tumor cells.  
 
 
Figure 22. TGF-β and ERK1 control furin levels in GIC cultured in differentiated conditions 
and in long-term glioma cell lines. A. T-325, ZH-161 and ZH-305 cells were cultured in NBM 
containing 5% FCS for 7 days. Cells were then transfected with siRNA targeting ERK1 and 48 h later 
treated with TGF-β2 for 24 h. Furin was analysed in the cell lysates by immunoblot. B. LN-229 and 
LN-308 cells were transfected with siRNA pools targeting ERK1 or non-targeting control. 48 h later 
cells were treated with TGF-β2 for 24 h. Furin was analysed in the cell lysates by immunoblot. 
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The reduction in furin levels following ERK1 gene silencing was associated with a 
reduction in pro-TGF-β1/2 processing with increased pro-TGF-β levels and 
decreased mature TGF-β levels (Figure 23). MEK1/2 inhibition did not significantly 
affect the number of spheres, but the spheres formed by GIC (T-325, ZH-161 and 
ZH-305) treated with U0126 were smaller, suggesting an inhibitory effect on cell 
proliferation as confirmed by reduced MTT metabolism (Figure 24). 
 
 
Figure 23. ERK1 gene silencing leads to reduced TGF-β processing in GIC. T-325, ZH-161 and 
ZH-305 cells were transfected with siRNA targeting ERK1. 24 h later cells were put in fresh media 
and further incubated for 72 h. Precursor and mature forms of TGF-β1 and TGF-β2 were then 
determined by immunoblot in the conditioned media. 
 
 
Figure 24. MEK1/2 inhibition reduces proliferation of GIC. Sphere formation assay in T-325, ZH-
161 and ZH-305 cells treated with 10 µM U0126 or solvent control for 15 days. Data are absorbance 
values after MTT addition (* p<0.05, **p<0.01, unpaired Student’s t-test). 
 
Targeting ERK1/2 also attenuated the immunosuppressive properties of GIC since 
treatment of ZH-161 and ZH-305 cells with U0126 decreased the induction of 
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CD4+CD25+FOXP3+ cells by conditioned media of ZH-161 (Figure 25) and ZH-305 
(data not shown). 
 
Figure 25. MEK1/2 inhibition reduces immunosuppressive properties of GIC. Human PBMC 
were treated with conditioned media from ZH-161 treated with U0126 or DMSO. Cells were stained 
for CD4 (FITC), CD25 (APC) and FOXP3 (PE). Scatter plots are gated on CD4+. P=0.0024, unpaired 






Glioblastoma is the most aggressive brain tumor in adults. Conventional 
glioblastoma treatment is based on tumor surgical resection, followed by radio-
chemotherapy. Despite current multimodal therapies, glioblastomas relapse and the 
prognosis is poor (Reifenberger et al., 2016). GIC have been attributed an important 
role in tumor initiation, therapy resistance and recurrence. In addition, 
immunosuppressive properties due to cell-to-cell interactions as well as due to the 
secretion of immunosuppressive cytokines, such as TGF-β, have been ascribed to 
GIC (Lathia et al., 2015). Indeed, TGF-β is a key cytokine in glioblastoma biology 
since it controls several hallmarks of the disease, including the tumorigenic activity 
of GIC (Joseph et al., 2013). GIC express high levels of TGF-β and TGF-β has been 
shown to promote maintenance of stemness properties of GIC (Ikushima et al., 
2009). Due to the role played in the malignant phenotype of glioblastoma, TGF-β 
has attracted attention as a potential target for glioblastoma treatment. Different 
approaches have been pursued to inhibit TGF-β, with the development of TGF-β 
oligonucleotides (Hau et al., 2007), anti-TGF-β antibodies (den Hollander et al., 
2015) and inhibitors of TGF-β signaling (Han et al., 2015). TGF-β signal transduction 
is mainly targeted using TGF- receptor inhibitors such as SD-208 (Uhl et al., 2004). 
In this work we pursued an alternative approach focusing on TGF-β processing and 
investigating the role played by PCSK in TGF-β processing in GIC. Among the 
PCSK candidates we identified furin as an extracellular regulator of TGF-β activity 
in GIC. Indeed, we demonstrated that furin is the main enzyme involved in TGF-β 
processing in GIC and that this process may take place to a greater extent 
extracellularly (Figure 12). These data thus allowed the identification of furin as a 
potential extracellular target to counteract TGF-β in gliomas. 
Furin and the other PCSK are deregulated in several pathological conditions, 
including cancer (Seidah and Prat, 2012). For this reason, PCSK have been 
considered as potential therapeutic targets in the past and several inhibitors have 
been generated so far. However, their use is limited by the lack of the strict 
specificity of the currently available molecules for the individual PCSK (Seidah and 
Prat, 2012). The use of oligonucleotides specific for furin may represent an 
alternative therapeutic strategy allowing to overcome the specificity issue. Recently, 
a phase I clinical trial based on DNA/autologous tumor cell vaccination in 
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combination with furin gene-silencing brought promising results (Senzer et al., 
2012). Another limitation of the therapeutic inhibition of furin as well as of some other 
PCSK is their ubiquitous expression. Beyond, furin processes a broad range of 
substrates which are essential for tissue homeostasis. Thus, inhibition of furin, in 
particular in case this is done in a systemic way, may lead to severe side effects on 
normal tissues. Thus, targeted strategies or local administration of the 
inhibitors/oligonucleotides are required. Interestingly according to the work 
presented here, furin, which was meant to act mainly intracellularly in the trans-Golgi 
network (Thomas, 2002), acts to a greater extent extracellularly in the case of TGF-
β processing in GIC. Thus, the development of furin blocking agents acting only 
extracellularly, such as cell non-permeable inhibitors or antibodies, may potentially 
represent a strategy to partially overcome the inhibition of the processing of other 
substrates than TGF-β. 
GIC express high levels of TGF-β. Autocrine production of TGF-β may be necessary 
to maintain GIC stemness and TGF-β signaling in the tumor microenvironment. 
Previous works suggested that in glioma cells TGF-β promotes its expression in an 
autocrine positive loop (Rodon et al., 2014). In this work, we uncovered the 
existence of an additional mechanism by which TGF-β sustains its activity, involving 
furin. Indeed, this work demonstrates a positive feedback loop where TGF-β 
promotes furin expression in GIC (Figure 16). Notably, the control of furin expression 
by TGF-β does not involve the canonical/SMAD-dependent signaling pathway 
(Figure 18), but it relies on the MEK/ERK pathway (Figure 19). Specifically, our 
results suggest that ERK1 controls basal furin levels in GIC and mediates the 
induction of furin by TGF-β2 (Figure 20). Importantly, the inhibition of the MEK1/2 
pathway translated into a reduction of TGF-β processing and decreased 
proliferation of GIC (Figure 23-24). 
The MEK/ERK pathway is a key regulatory signaling pathway involved in the control 
of cell survival, proliferation and differentiation. The MEK/ERK cascade is often 
deregulated in cancers, mainly as a consequence of mutations affecting the up-
stream regulators Raf serine/threonine kinases and RAS small GTPase (Zhao and 
Adjei, 2014). Also, since the ERK signaling acts downstream to receptors tyrosine 
kinases such as EGFR, ERK activation is increased when receptor tyrosine kinases 
are overexpressed or more active due to mutations (Zhao and Adjei, 2014). In 
glioblastoma, several mutations affect the receptor tyrosine kinase/RAS/Raf 
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signaling pathway and overexpression or mutation of EGFR are common (Verhaak 
et al., 2010; Reifenberger et al., 2016). Indeed, ERK activity is up-regulated in 
glioblastoma (Lopez-Gines et al., 2008). Because of its aberrant regulation in 
cancers, the ERK pathway has attracted attention as a potential therapeutic target, 
with the consequent development of different MEK1/2 pharmacological inhibitors, 
such as selumetinib, trametinib and binimetinib, which are at present under clinical 
investigation in cancer patients (Zhao and Adjei, 2014). Our data suggest that ERK1 
inhibition in GIC may also affect TGF-β levels by attenuating furin expression. Thus, 
the specific block of ERK1 signaling may inhibit the autocrine loop by which TGF-β 
promotes its processing. In conclusion, due to the elucidation of the autocrine loop 
by which TGF-β sustains its expression and processing in GIC, involving furin and 
ERK1, this work may be useful to develop more sophisticated therapeutic strategies 






6.2 Transforming growth factor (TGF)-β induces the splice variants extra-
domain A (EDA) and extra-domain B (EDB) of fibronectin to control TGF-β 
superfamily activity in endothelial cells 
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6.2.1.1 TGF-β1 and TGF-β2 induce FN, EDA+FN and EDB+FN expression in 
endothelial cells. 
We first investigated the expression of total FN and of the FN isoforms containing 
the extra-domains A and B in ten human glioblastoma sections. We used the 
antibodies IST4, reacting with a FN domain common to all FN isoforms, IST9, 
reacting with the EDA domain, and C6, specific for EDB+FN (Figure 26). Tumor-
associated vessels showed high levels of FN and of the two isoforms EDA+FN and 
EDB+FN, whereas the bulk tumor was negative (Figure 27). Accordingly, an 
analysis of freshly dissociated glioblastoma samples showed that FN, EDA+FN and 
EDB+FN were specifically expressed in the CD31+ cell fraction (Figure 28). 
 
 
Figure 26. Schematic representation of the modular structure of FN. The target regions of the 
monoclonal antibodies specific for the FN type III repeats 5 (IST-4), EDA+FN (IST-9) and EDB+FN 





Figure 27. EDA+FN and EDB+FN are expressed in glioblastoma tumor vasculature. Total FN, 





Figure 28. FN, EDA+FN and EDB+FN are preferentially expressed in CD31+ cells in 
glioblastoma. Total FN, EDA+FN and EDB+FN mRNA levels were determined in CD31+ versus 
CD31- cells isolated from freshly dissociated glioblastoma tissues by RT-PCR. 
 
Considering the vascular localization of FN and its isoforms in glioblastoma we 
aimed at investigating the endothelial compartment in appropriate in vitro cell 
models. As alternative splicing of FN respectively the generation of EDA+FN and 
EDB+FN is mainly regulated by TGF-β in several cell types, we used human brain-
derived microvascular endothelial cells (hCMEC) to investigate the effect of TGF-β1 
and TGF-β2 treatment on FN, EDA+FN and EDB+FN levels. Indeed, treatment with 
both TGF-β1 and TGF-β2 increased mRNA and protein levels of total FN, EDA+FN 
and EDB+FN (Figure 29A). In order to decipher the molecular mechanism by which 
TGF-β1 and TGF-β2 induce FN expression in hCMEC, we first used the ALK-5-
specific inhibitor SD-208. SD-208 abolished the TGF-β1- and TGF-β2-mediated 
induction of FN, EDA+FN and EDB+FN on both mRNA and protein level (Figure 
29A), indicating that the process is ALK-5-dependent and equally valid for TGF-β1 
and TGF-β2. To further specify the signal transduction pathway downstream to 
TGF-β receptors, we first investigated the potential involvement of the SMAD 
signaling pathway. Gene silencing of SMAD4 inhibited the TGF-β1- and TGF-β2-



















































































































































indicating the involvement of the SMAD signaling pathway (Figure 29B, data for 
TGF-β1 not shown). In order to investigate the R-SMAD involved in the process, we 
performed gene silencing of SMAD2 and SMAD3. Gene silencing of SMAD3, but 
not of SMAD2 (Figure 29C, left upper panel), abolished the TGF-β1- and TGF-β2-
dependent induction of FN, EDA+FN and EDB+FN on mRNA level (data for TGF-
β1 not shown). In addition, gene silencing of SMAD3 reduced the relative fraction of 
FN molecules containing the EDB domain by two-fold, whereas the relative fraction 
of FN molecules containing EDA remained unchanged (Figure 29C, upper panels). 
These data suggest a specific role for SMAD3 in the control of the splicing of the 
EDB domain. The inhibitory effect of SMAD3 gene silencing on TGF-β1- and TGF-
β2-mediated induction of FN, EDA+FN and EDB+FN was confirmed on protein 
levels (Fig. 29C, lower panels, data for TGF-β1 not shown).  
Since a role for JNK in the TGF-β-dependent induction of FN expression has been 
reported in human fibrosarcoma cells (Hocevar et al., 1999) and in light of the known 
cross-talk between canonical SMAD-dependent and non-canonical SMAD-
independent TGF-β signaling pathways, we also explored the potential role of JNK 
in our model. The JNK-specific inhibitor SP600125 did not influence TGF-β2-
dependent induction of total FN or EDA+FN, but it abolished the TGF-β2-dependent 
induction of EDB+FN on mRNA and protein levels (Figure 30). These data suggest 
that the JNK signaling pathway is involved in the control of EDB splicing in hCMEC 
cells. Inhibition of the other branches of the non-canonical TGF-β signaling cascade 
using specific inhibitors for p38, MEK1/2 and AKT neither affected FN on basal level 
nor its TGF-β2-dependent induction (data not shown), pointing towards a specific 





Figure 29. TGF-β1 and TGF-β2 induce EDA+/EDB+FN expression in hCMEC in an ALK5- and 
SMAD3/SMAD4-dependent manner. In all experiments FN, EDA+FN and EDB+FN levels were 
determined 48 h post TGF-β treatment on mRNA level by RT-PCR and 72 h post TGF-β treatment 
on protein level by ELISA. Data are expressed as means of triplicates ± SD. A. FN, EDA+FN and 
EDB+FN mRNA (left panel) and protein levels (other panels) in hCMEC cells incubated with 1 µM 
SD-208 or DMSO as solvent control for 1 h and then treated with 5 ng/ml TGF-β1 or TGF-β2. B. FN, 
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EDA+FN and EDB+FN mRNA (left panel) and protein (other panels) levels in hCMEC transfected 
with siRNA targeting SMAD4 or non-targeting control and treated with 5 ng/ml TGF-β2 24 h post-
transfection. C. FN, EDA+FN and EDB+FN mRNA levels (left upper panel) in hCMEC transfected 
with siRNA targeting SMAD2, SMAD3 or non-targeting control and treated with 5 ng/ml TGF-β2 24 
h post-transfection. The fraction of FN molecules containing the EDA domain (EDA+FN/total FN) or 
EDB domain (EDB+FN/total FN), using the RT-PCR data reported on the left panel, are indicated. 
FN, EDA+FN and EDB+FN protein levels in hCMEC transfected with siRNA targeting SMAD3 or 
non-targeting control and treated with 5 ng/ml TGF-β2 24 h post-transfection (lower panels). 
 
 
Figure 30. TGF-β2-mediated induction of EDB+FN involves the JNK pathway. FN, EDA+FN and 
EDB+FN mRNA (left panel) and protein levels (other panels) in hCMEC pre-incubated with 10 µM 
SP600125 for 2 h and then treated with 5 ng/ml TGF-β2 for 48 h (left panel) or 72 h (other panels). 
 
In order to investigate this process in a model closely reflecting the in vivo situation, 
we analyzed the effect of TGF-β1 and TGF-β2 on FN in human glioblastoma-derived 
endothelial cells (GMEC) derived from freshly dissociated tumor tissue by isolating 
CD31+ cells. TGF-β2 induced the expression of FN, EDA+FN and EDB+FN in the 
two patient-derived cell lines ZH-459 CD31+ and ZH-613 CD31+ (Figure 31A, B). 
We then investigated the molecular mechanism in the cell line ZH-613. In line with 
our results for hCMEC (Figure 29), TGF-β2-induced expression of FN, EDA+FN and 
EDB+FN was ALK-5-dependent (Figure 31B) and SMAD3/SMAD4-dependent 
(Figure 31C). In CD31+ cells derived from another glioblastoma patient (ZH-616), 
TGF-β2 did not induce FN, EDA+FN and EDB+FN, but the gene silencing of SMAD3 




Figure 31. TGF-β1 and TGF-β2 induce EDA+/EDB+FN expression in CD31+ cells derived from 
glioblastoma in a ALK-5- and SMAD4/SMAD3-dependent manner. A. FN, EDA+FN and EDB+FN 
mRNA levels in ZH-459 CD31+ cells treated with 5 ng/ml TGF-β1 or TGF-β2 for 48 h. B. FN, EDA+FN 
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and EDB+FN mRNA levels in ZH-613 CD31+ cells incubated for 1 h with 1 µM SD-208 or DMSO as 
solvent control and then treated with 5 ng/ml TGF-β2 for 48 h. C. FN, EDA+FN and EDB+FN mRNA 
levels in ZH-613 CD31+ cells transfected with siRNA targeting SMAD3, SMAD4 or non targeting 
control and then treated with 5 ng/ml TGF-β2 24 h post-transfection for 48 h. D. FN, EDA+FN and 
EDB+FN mRNA levels in ZH-616 CD31+ cells transfected with siRNA targeting SMAD3, SMAD4 or 
non targeting control and then treated with 5 ng/ml TGF-β2 24 h post-transfection for 48 h. Data are 
mean of triplicates ± SD. 
 
 
6.2.2.2 EDA+FN and EDB+FN promote TGF-β superfamily/SMAD1,5 signaling 
in hCMEC. 
To investigate the potential control of TGF-β signaling by EDA+FN and EDB+FN in 
endothelial cells, we performed transient gene silencing of EDA+FN or EDB+FN in 
hCMEC (Figure 32A, left panel) and checked for phosphorylation levels of R-SMAD 
(Figure 32A). The levels of pSMAD1,5 were reduced in both siEDA+FN and 
siEDB+FN gene-silenced cells. Cells with EDA+FN gene silencing showed also 
reduced leves of pSMAD3. The levels of pSMAD2 were unaffected (Figure 32A). To 
evaluate the signaling cascade further downstream, we determined mRNA levels of 
ID-1 and PAI-1 as downstream targets of the putative ALK-1/pSMAD1,5,8 and ALK-
5/pSMAD2,3 branches, respectively. The gene silencing of EDA+FN and EDB+FN 
decreased ID-1 and increased PAI-1 expression levels in hCMEC cells (Figure 32B).  
Since the gene silencing of EDA+FN also affected total levels of FN and EDB+FN 
levels (see Figure 32A, left panel), to confirm the specific involvement of the EDA 
and EDB domains, we used a different approach, based on the use of recombinant 
FN fragments including or excluding the EDA and EDB domains (Figure 33A). 
HCMEC cells treated with a recombinant FN fragment containing the EDB domain 
and adjacent FN type III domains 7, 8 and 9 (7-EDB-8-9) showed reduced levels of 
pSMAD1,5 compared with untreated cells or cells treated with the corresponding 
FN fragment lacking the EDB domain (7-8-9). The levels of pSMAD2 and pSMAD3 
were unchanged (Figure 33B). On mRNA levels the treatment with 7-EDB-8-9 
decreased the levels of ID-1 and increased the levels of PAI-1 (Figure 33C). 
Treatment with the recombinant EDB domain alone (without the adjacent domains 
7, 8 and 9) had only minor effects on either pSMAD1,5 and ID-1 or PAI-1 levels, 
indicating the involvement of flanking domains in mediating the EDB effect. 
Compared to untreated cells or cells treated with the recombinant fragments 
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including the two flanking EDA domains 11-12 and lacking EDA, hCMEC cells 
treated with the recombinant EDA domain alone showed decreased levels of 
pSMAD1,5 whereas the levels of pSMAD2 and pSMAD3 were unaffected. 
pSMAD1,5 levels were reduced in cells treated with the FN fragment 11-12 to a 
lesser extent than in cells treated with the EDA domain alone (Figure 33B). On 
mRNA level, EDA treatment reduced the levels of ID1 and increased the levels of 
PAI-1 (Figure 33C). These data suggest that both the EDA and the EDB domains 
of FN are involved in the control of TGF-β superfamily signaling in hCMEC cells. 
 
Figure 32. The gene silencing of EDA+FN and EDB+FN in hCMEC decreases SMAD1,5 
phosphorylation. A. hCMEC cells were transfected with siRNA targeting the EDA or EDB domain 
of FN or non-targeting control siRNA. At 24 h post transfection cells were transferred to a new dish 
and cultured in full medium. At 48 h post transfection cells were put in serum-free medium for 48 h. 
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Concentrated conditioned culture media were analyzed for the levels of total FN, EDA+FN and 
EDB+FN (upper left panel). The levels of phosphorylated and total SMAD1,5, SMAD2 and SMAD3 
were analyzed in cell lysates. The densitometry analysis of the immunoblot is indicated. B. FN, 
EDA+FN, EDB+FN, ID-1 and PAI-1 mRNA levels in hCMEC cells were determined by RT-PCR 
following gene silencing of EDA+FN or EDB+FN and compared to non-targeting control. Data are 
expressed as mean ± SD (**P<.01, ***P<.001, ****P<.0001, one-way Anova followed by Tukey’s post 
hoc test 95% CI). 
 
Figure 33. Treatment of hCMEC with recombinant fibronectin fragments containing the EDA 
and EDB domains reduces pSMAD1,5 levels. A. Recombinant fragments of the FN molecule 
adjacent to the EDA and EDB domains including and excluding the extra-domains A and B used in 
this study. B. HCMEC cells were treated with the indicated FN recombinant fragments at 1 mM for 
48 h. Levels of phosphorylated and total SMAD1,5, SMAD2 and SMAD3 were determined in cell 
lysates by immunoblot. C. HCMEC cells were treated for 24 h with the indicated recombinant FN 
fragments. ID-1 and PAI-1 mRNA levels were determined by RT-PCR. Data are expressed as mean 
± SD (**P<.01, ***P<.001, ****P<.0001 treated vs untreated cells, ++++P<.0001 cells treated with 7-
EDB-8-9 vs cells treated with 7-8-9 or EDB, one-way Anova followed by Tukey’s post hoc test 95% 



































































































6.2.2.3 FN modulates α-SMA expression in endothelial cells derived from 
glioblastoma.  
Since it has been shown that endothelial cells undergo EndMT and express α-SMA 
in glioblastoma (Huang et al., 2016) and that EDA+FN controls α-SMA expression 
in fibroblasts (Serini et al., 1998), we asked if EDA+FN or EDB+FN modulate α-SMA 
expression in endothelial cells derived from glioblastoma. To this aim we performed 
the selective gene silencing of EDA+FN or EDB+FN in four CD31+ cells lines 
derived from freshly dissociated glioblastoma tissue (ZH-464, ZH-483-2, ZH-613, 
ZH-616). In all the cell lines, EDA+FN and EDB+FN gene silencing reduced α-SMA 
mRNA expression (Figure 34), suggesting a role for EDA+FN and EDB+FN in the 
regulation of α-SMA levels in glioblastoma-derived endothelial cells. 
 
 
Figure 34. EDA+FN and EDB+FN control α-SMA expression in glioblastoma-derived CD31+ 
cells. α-SMA mRNA levels were determined by RT-PCR in the indicated CD31+ cell lines upon 
specific gene-silencing of EDA+FN, EDB+FN or non-targeting control. Data are expressed as mean 





The fibronectin splice isoforms containing the EDA and EDB domains, EDA+FN and 
EDB+FN, are highly expressed in the vasculature and in the heart of the developing 
embryo (Astrof and Hynes, 2009). After completion of developmental processes, 
both EDA+FN and EDB+FN are down-regulated and are almost undetectable in 
mature adult blood vessels and tissues, with the exception of tissues undergoing 
physiological remodeling and angiogenesis, like the uterus and the ovary. By 
contrast, during pathological tissue remodeling, in chronically inflamed tissues and 
tumors, these FN isoforms are re-expressed and accumulate around newly formed 
vessels (Astrof and Hynes, 2009). In particular, EDB+FN is considered a marker of 
angiogenesis since its expression in the adult blood vasculature is strictly restricted 
to vessels undergoing neo-angiogenesis (Castellani et al., 1994). Previous reports 
showed that FN is up-regulated in glioblastoma vasculature (Dieterich et al., 2012) 
and that the percentage of vessels expressing EDB+FN correlates with tumor grade 
in gliomas (Castellani et al., 2002). Here we show that the expression of FN and not 
only of the two isoforms EDB+FN, but also of the isoform EDA+FN is abundant and 
restricted to tumor vasculature in glioblastoma (Figure 27). In addition we show that 
CD31+ cells are the main source of FN in glioblastoma ex vivo (Figure 28). 
Glioblastomas are characterized by high vascular density and vascular 
abnormalization with the typical formation of glomeruloid vascular structures (Wen 
and Kesari, 2008). TGF-β2 is highly expressed in glioblastoma and it has been 
attributed a central role in both tumor angiogenesis and vessels abnormalization. A 
direct role for TGF-β2 in regulating the phenotype of glioblastoma vessels, including 
the expression of components of the extracellular matrix, has been proposed. 
Indeed SMAD2/SMAD4 and SMAD3/SMAD4 complexes localize mainly to the 
vascular and peri-vascular areas in glioblastoma (Dieterich et al., 2012). TGF-β 
induces FN in several cell types (Ignotz and Massague, 1986) and is one of the best 
characterized modulator of the alternative splicing affecting the EDA and EDB 
domains (Balza et al., 1988; Borsi et al., 1990; Viedt et al., 1995). Here we show 
that TGF-β2 induces FN, EDA+FN and EDB+FN in hCMEC cells (Figure 29) and in 
CD31+ cells isolated from freshly dissociated human glioblastoma tissue (Figure 
31). Induction of FN, EDA+FN and EDB+FN by TGF-β2 involves the SMAD-
dependent/canonical TGF-β signaling pathway and specifically SMAD3. These data 
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suggest a role for TGF-β2/SMAD3/SMAD4 signaling in the control of the expression 
of FN and its splice isoforms EDA+FN and EDB+FN in glioblastoma vasculature.  
 
In endothelial cells TGF-β may activate both the ALK-5/SMAD2,3-dependent and 
the ALK-1/SMAD1,5,8-dependent signaling pathways. The activation of the ALK-
5/SMAD2,3-dependent signaling branch may promote ECM deposition and 
endothelium stabilization and maturation, whereas the ALK-1/SMAD1,5,8-
dependent signaling branch may contribute to the activation of endothelial cells, 
promoting their migration and proliferation (Goumans et al., 2002). It has been 
proposed that the equilibrium in the activation of these two signaling pathways finally 
determines the effect of TGF-β on endothelial state (Goumans et al., 2002). 
Previous reports suggested that in human microvascular endothelial cells, FN and 
its receptor integrin α5β1 increase the ALK-1/SMAD1,5,8-dependent signaling 
branch, by promoting the formation of complexes of ALK-1 and the co-receptor 
endoglin (Tian et al., 2012).  
Despite the extensively documented expression of EDA+FN and EDB+FN in neo-
vessels and in endothelial cells undergoing EndMT, the precise role played by 
EDA+FN and EDB+FN in vascular morphogenesis and plasticity is not yet clear 
(Astrof and Hynes, 2009). Double null mice for the EDA and EDB domains die at 
embryonic stage with severe vasculature defects (Astrof et al., 2007). By contrast, 
single knockout mice for EDA and EDB containing FN isoforms are vital, show 
normal vasculogenesis (Fukuda et al., 2002; Muro et al., 2008) and normal 
physiological and tumor angiogenesis (Astrof et al., 2004). In the present work we 
suggest a role for EDA+FN and EDB+FN in the modulation of TGF-β superfamily 
signaling in endothelial cells. Specifically we show that EDA+FN and EDB+FN affect 
TGF-β superfamily/SMAD1,5-dependent signaling by increasing the 
phosphorylation of SMAD1,5 in hCMEC (Figure 32-33). 
 
Previous studies demonstrated that glioblastoma vessels express several markers 
of EndMT (Dieterich et al., 2012) and that glioblastoma-derived endothelial cells 
display endothelial plasticity (Huang et al., 2016). By undergoing the process of 
EndMT, endothelial cells acquire a fibroblast-like phenotype, become more invasive 
and drive the abnormal vascularization which is typical of glioblastoma. During this 
process glioblastoma-derived endothelial cells express mesenchymal markers, 
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including α-SMA (Huang et al., 2016). α-SMA, the actin isoform typical of vascular 
smooth muscle cells and functionally associated with cell contractility, is one of the 
most important markers of EndMT. It has been reported that, by promoting TGF-β1 
activation and α-SMA expression, EDA+FN favors the conversion of fibroblasts into 
myofibroblasts (Serini et al., 1998; Muro et al., 2008; White et al., 2008). In the 
present work we confirmed that glioblastoma-derived endothelial cells express α-
SMA and show that both EDA+FN and EDB+FN promote α-SMA expression in 
glioblastoma-derived endothelial cells (Figure 34). These data suggest that FN and 
the two isoforms EDA+FN and EDB+FN, which are up-regulated in glioblastoma 
vessels and are known markers of EndMT, may contribute to the EndMT process 
by promoting the expression of α-SMA in tumor-associated endothelial cells. 
 
In summary, in the present work we show that TGF-β1 and TGF-β2 induce FN, 
EDA+FN and EDB+FN in hCMEC and in CD31+ cells derived from human 
glioblastoma tissues. In turn, EDA+FN and EDB+FN modulate TGF-β superfamily 
signaling by increasing the phosphorylation of SMAD1,5 in hCMEC and promote the 
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